{
    "drugSuccessPredictions": [
      {
        "drugId": "6386",
        "displayName": "trastuzumab",
        "drugPrograms": [
          {
            "company": {
              "id": "15414",
              "name": "Chugai Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Mar-2019",
            "endDate": "",
            "statusDate": "15-Mar-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "15-Mar-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "2054",
              "name": "Hematological neoplasm"
            },
            "country": {
              "id": "EU",
              "name": "Europe (GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Feb-2023",
            "endDate": "13-Oct-2030",
            "statusDate": "10-Feb-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "73%",
            "timeToRegistration": "6.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "10-Feb-2023",
                "endDate": "16-Oct-2029",
                "successPercentage": "77%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-Oct-2029",
                "endDate": "03-Sep-2030",
                "successPercentage": "95%",
                "predictedDateL50": "03-Dec-2028",
                "predictedDateU50": "25-Feb-2030",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "03-Sep-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-May-2030",
                "predictedDateU50": "13-Oct-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Oct-2029",
                "milestoneExtendedDate": "31-Oct-2029",
                "notes": "In February 2023, a phase II/III trial (NCT05722886) in patients with hematological neoplasms was expected to complete in October 2029 [ <ulink linkID=\"2822441\" linkType=\"Reference\">  2822441 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe (GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Feb-2023",
            "endDate": "09-Oct-2030",
            "statusDate": "10-Feb-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "64%",
            "timeToRegistration": "6.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "10-Feb-2023",
                "endDate": "16-Oct-2029",
                "successPercentage": "67%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-Oct-2029",
                "endDate": "29-Aug-2030",
                "successPercentage": "95%",
                "predictedDateL50": "16-Nov-2028",
                "predictedDateU50": "24-Feb-2030",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-Aug-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "20-May-2030",
                "predictedDateU50": "09-Oct-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Oct-2029",
                "milestoneExtendedDate": "31-Oct-2029",
                "notes": "In February 2023, a phase II/III trial (NCT05722886) in patients with advanced solid tumors was expected to complete in October 2029 [ <ulink linkID=\"2822441\" linkType=\"Reference\">  2822441 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19453",
              "name": "Genentech Inc"
            },
            "indication": {
              "id": "740",
              "name": "Uterus tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Jun-2011",
            "endDate": "",
            "statusDate": "30-Jun-2011",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Jun-2011",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19453",
              "name": "Genentech Inc"
            },
            "indication": {
              "id": "4299",
              "name": "Salivary gland cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Jun-2017",
            "endDate": "",
            "statusDate": "30-Apr-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Jun-2017",
                "endDate": "30-Apr-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Apr-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "24470",
        "displayName": "givinostat",
        "drugPrograms": [
          {
            "company": {
              "id": "17278",
              "name": "Italfarmaco SpA"
            },
            "indication": {
              "id": "2020",
              "name": "Duchenne dystrophy"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "30-Sep-2006",
            "endDate": "22-Oct-2024",
            "statusDate": "05-Sep-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "0.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Sep-2006",
                "endDate": "01-Jun-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "10.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Jun-2017",
                "endDate": "05-Sep-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Sep-2023",
                "endDate": "04-Sep-2024",
                "successPercentage": "86%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Sep-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-May-2024",
                "predictedDateU50": "22-Oct-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Positive Opinion",
                "milestoneDate": "11-May-2012",
                "milestoneExtendedDate": "",
                "notes": null,
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "04-Jul-2012",
                "milestoneExtendedDate": "",
                "notes": null,
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "27-Apr-2020",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, phase III study (NCT02851797; EPYDIS) positive interim data were reported for givinostat in Duchenne muscular dystrophy [<ulink linkType=\"Reference\" linkID=\"2270703\">2270703</ulink>].  </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In April 2020, phase III study (NCT02851797; EPYDIS) final analysis results were expected in 2022 for givinostat in Duchenne muscular dystrophy [<ulink linkType=\"Reference\" linkID=\"2270703\">2270703</ulink>].  </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In October 2020, the phase III study (NCT02851797; EPYDIS) first results were expected in June 2022 [ <ulink linkID=\"2339251\" linkType=\"Reference\"> 2339251 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "25-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, positive topline data from a phase III study (NCT02851797; EPYDIS) for the treatment of Duchenne muscular dystrophy were reported [ <ulink linkID=\"2694392\" linkType=\"Reference\"> 2694392 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "25-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, primary end point as met in a phase III study (NCT02851797; EPYDIS) for the treatment of Duchenne muscular dystrophy were reported [ <ulink linkID=\"2694392\" linkType=\"Reference\"> 2694392 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "05-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, EMA accepted and validated Marketing Authorization Application (MAA) of givinostat for the treatment of DMD based on the safety and efficacy data from the phase III EPIDYS study and EMA started its regulatory review process [ <ulink linkID=\"3086342\" linkType=\"Reference\"> 3086342 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17278",
              "name": "Italfarmaco SpA"
            },
            "indication": {
              "id": "2020",
              "name": "Duchenne dystrophy"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug, Fast Track, Rare Pediatric Disease, Priority Review",
            "startDate": "06-Jun-2017",
            "endDate": "15-May-2024",
            "statusDate": "29-Jun-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "0.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "06-Jun-2017",
                "endDate": "29-Jun-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Jun-2023",
                "endDate": "04-Apr-2024",
                "successPercentage": "86%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Apr-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Jan-2024",
                "predictedDateU50": "15-May-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "27-Apr-2020",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, phase III study (NCT02851797; EPYDIS) positive interim data were reported for givinostat in Duchenne muscular dystrophy [<ulink linkType=\"Reference\" linkID=\"2270703\">2270703</ulink>].  </para>",
                "newMilestone": false
              },
              {
                "title": "Fast Track",
                "status": "Granted",
                "milestoneDate": "12-Oct-2020",
                "milestoneExtendedDate": "",
                "notes": "By October 2020, the US FDA granted Fast Track designation for treatment of Duchenne Muscular Dystrophy [<ulink linkType=\"Reference\" linkID=\"2339251\">2339251</ulink>].  </para>",
                "newMilestone": false
              },
              {
                "title": "Rare Pediatric Disease",
                "status": "Granted",
                "milestoneDate": "12-Oct-2020",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the US FDA granted Rare Pediatric Disease designation for treatment of young males suffering from Duchenne Muscular Dystrophy [<ulink linkType=\"Reference\" linkID=\"2339251\">2339251</ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In April 2020, phase III study (NCT02851797; EPYDIS) final analysis results were expected in 2022 for givinostat in Duchenne muscular dystrophy [ <ulink linkID=\"2270703\" linkType=\"Reference\"> 2270703 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In October 2020, the phase III study (NCT02851797; EPYDIS) first results were expected in June 2022 [<ulink linkType=\"Reference\" linkID=\"2339251\">2339251</ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "25-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, positive topline data from a phase III study (NCT02851797; EPYDIS) for the treatment of Duchenne muscular dystrophy were reported [ <ulink linkID=\"2694392\" linkType=\"Reference\"> 2694392 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "25-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, primary end point as met in a phase III study (NCT02851797; EPYDIS) for the treatment of Duchenne muscular dystrophy were reported [ <ulink linkID=\"2694392\" linkType=\"Reference\"> 2694392 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Priority Review",
                "status": "Granted",
                "milestoneDate": "29-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, Priority review was granted by the US FDA for the treatment of DMD [ <ulink linkID=\"2994366\" linkType=\"Reference\"> 2994366 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "29-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, NDA filing was accepted by the US FDA for the treatment of DMD. At that time, PDUFA date was expected in December 21, 2023 [ <ulink linkID=\"2994366\" linkType=\"Reference\"> 2994366 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "21-Dec-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, PDUFA date was expected in December 21, 2023 by the US FDA for the treatment of DMD [ <ulink linkID=\"2994366\" linkType=\"Reference\"> 2994366 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "21-Mar-2024",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, US FDA extended the PDUFA target action date, is March 21, 2024 [ <ulink linkID=\"3513525\" linkType=\"Reference\"> 3513525 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17278",
              "name": "Italfarmaco SpA"
            },
            "indication": {
              "id": "2319",
              "name": "Polycythemia vera"
            },
            "country": {
              "id": "EU",
              "name": "Europe (DE, GB, IT)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "31-Dec-2007",
            "endDate": "14-Oct-2027",
            "statusDate": "17-Dec-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "33%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Dec-2007",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "15.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "24-Aug-2026",
                "successPercentage": "40%",
                "predictedDateL50": "21-Sep-2022",
                "predictedDateU50": "25-Jul-2024",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "24-Aug-2026",
                "endDate": "26-Aug-2027",
                "successPercentage": "87%",
                "predictedDateL50": "06-Jul-2025",
                "predictedDateU50": "01-Feb-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Aug-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Apr-2027",
                "predictedDateU50": "14-Oct-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Positive Opinion",
                "milestoneDate": "03-Dec-2009",
                "milestoneExtendedDate": "",
                "notes": null,
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "03-Feb-2010",
                "milestoneExtendedDate": "",
                "notes": null,
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "18-Mar-2021",
                "milestoneExtendedDate": "",
                "notes": "In March 2021, first interim analysis results from phase I/II   in PV patients  were published  [<ulink linkType=\"Reference\" linkID=\"2423343\">2423343</ulink>], [<ulink linkType=\"Reference\" linkID=\"2425901\">2425901</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Jul-2021",
                "notes": "In March 2021, a global  phase III trial with givinostat in polycythemia vera (PV)  patients was expected to initiate in mid-2021 [<ulink linkType=\"Reference\" linkID=\"2423343\">2423343</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "DE",
              " GB",
              " IT"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17278",
              "name": "Italfarmaco SpA"
            },
            "indication": {
              "id": "3289",
              "name": "Becker muscular dystrophy"
            },
            "country": {
              "id": "EU",
              "name": "EU (IT, NL)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "12-Dec-2017",
            "endDate": "25-Mar-2029",
            "statusDate": "12-Dec-2017",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "20%",
            "timeToRegistration": "5.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Dec-2017",
                "endDate": "29-Apr-2025",
                "successPercentage": "62%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "29-Apr-2025",
                "endDate": "27-Jan-2028",
                "successPercentage": "36%",
                "predictedDateL50": "18-Mar-2024",
                "predictedDateU50": "06-Feb-2026",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Jan-2028",
                "endDate": "03-Feb-2029",
                "successPercentage": "88%",
                "predictedDateL50": "01-Dec-2026",
                "predictedDateU50": "11-Jul-2028",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "03-Feb-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Oct-2028",
                "predictedDateU50": "25-Mar-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Positive Opinion",
                "milestoneDate": "21-Jun-2018",
                "milestoneExtendedDate": "",
                "notes": null,
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "31-Jul-2018",
                "milestoneExtendedDate": "",
                "notes": null,
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Mar-2021",
                "milestoneExtendedDate": "31-Mar-2021",
                "notes": "In July 2020, a phase II study (NCT03238235) for Becker Muscular Dystrophy, was expected to complete in March 2021 [<ulink linkType=\"Reference\" linkID=\"2053120\">2053120</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Other Outcome",
                "milestoneDate": "26-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, topline results from phase II trial (NCT03238235) in patients with Becker muscular dystrophy (BMD) were reported [ <ulink linkID=\"2483348\" linkType=\"Reference\">  2483348 </ulink> ]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "IT",
              " NL"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "54730",
        "displayName": "sotatercept",
        "drugPrograms": [
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "17",
              "name": "Anemia"
            },
            "country": {
              "id": "EU",
              "name": "EU (FR)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Nov-2012",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "28-Nov-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "FR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "17",
              "name": "Anemia"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "15331",
              "name": "Celgene Corporation"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "2369",
              "name": "Beta thalassemia"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Oct-2012",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "10-Oct-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "2436",
              "name": "Myelofibrosis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Feb-2013",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "28-Feb-2013",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1867",
              "name": "Pulmonary hypertension"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Dec-2021",
            "endDate": "30-Dec-2029",
            "statusDate": "29-Dec-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "6.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "29-Dec-2021",
                "endDate": "19-May-2026",
                "successPercentage": "42%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "19-May-2026",
                "endDate": "31-Jan-2029",
                "successPercentage": "12%",
                "predictedDateL50": "19-Sep-2025",
                "predictedDateU50": "31-Oct-2026",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Jan-2029",
                "endDate": "27-Nov-2029",
                "successPercentage": "85%",
                "predictedDateL50": "14-Dec-2027",
                "predictedDateU50": "11-Jul-2029",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Nov-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-Aug-2029",
                "predictedDateU50": "30-Dec-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "19-May-2026",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, a phase II trial (NCT04945460; CADENCE) for Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) Due to Heart Failure With Preserved Ejection Fraction (HFpEF) was expected to complete in May 2026 [ <ulink linkID=\"3314863\" linkType=\"Reference\"> 3314863 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1867",
              "name": "Pulmonary hypertension"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Dec-2021",
            "endDate": "28-Feb-2030",
            "statusDate": "29-Dec-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "6.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "29-Dec-2021",
                "endDate": "19-May-2026",
                "successPercentage": "45%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "19-May-2026",
                "endDate": "31-Jan-2029",
                "successPercentage": "13%",
                "predictedDateL50": "19-Sep-2025",
                "predictedDateU50": "31-Oct-2026",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Jan-2029",
                "endDate": "20-Jan-2030",
                "successPercentage": "84%",
                "predictedDateL50": "14-Dec-2027",
                "predictedDateU50": "11-Jul-2029",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-Jan-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-Sep-2029",
                "predictedDateU50": "28-Feb-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "19-May-2026",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, a phase II trial (NCT04945460; CADENCE) for Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) Due to Heart Failure With Preserved Ejection Fraction (HFpEF) was expected to complete in May 2026 [ <ulink linkID=\"3314863\" linkType=\"Reference\"> 3314863 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3510",
              "name": "Pulmonary artery hypertension"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-May-2018",
            "endDate": "17-Oct-2024",
            "statusDate": "26-Oct-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "91%",
            "timeToRegistration": "0.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "22-May-2018",
                "endDate": "24-Feb-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "24-Feb-2021",
                "endDate": "26-Oct-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Oct-2023",
                "endDate": "06-Sep-2024",
                "successPercentage": "91%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-Sep-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-May-2024",
                "predictedDateU50": "17-Oct-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "10-Oct-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, positive topline data were reported from the phase III STELLAR trial demonstrating the primary endpoint to have been met with a significant improvement in the 6-min walk distance at 24 weeks [ <ulink linkID=\"2748942\" linkType=\"Reference\">  2748942 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2023, new data from a phase III trial (NCT04576988; STELLAR) for the treatment of pulmonary arterial hypertension were expected to present in March 2023 [ <ulink linkID=\"2828252\" linkType=\"Reference\"> 2828252 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "26-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "By October 2023, the NDA was submitted to the EMA for the treatment of PAH [ <ulink linkID=\"3482172\" linkType=\"Reference\"> 3482172 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3510",
              "name": "Pulmonary artery hypertension"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Jan-2021",
            "endDate": "15-Nov-2024",
            "statusDate": "22-Nov-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "19%",
            "timeToRegistration": "0.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "25-Jan-2021",
                "endDate": "10-Dec-2023",
                "successPercentage": "21%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "08-Oct-2024",
                "successPercentage": "89%",
                "predictedDateL50": "16-Jun-2023",
                "predictedDateU50": "11-Apr-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-Oct-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "27-Jun-2024",
                "predictedDateU50": "15-Nov-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "10-Oct-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, positive topline data were reported from the phase III STELLAR trial demonstrating the primary endpoint to have been met with a significant improvement in the 6-min walk distance at 24 weeks [ <ulink linkID=\"2748942\" linkType=\"Reference\">  2748942 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2023, new data from a phase III trial (NCT04576988; STELLAR) for the treatment of pulmonary arterial hypertension were expected to present in March 2023 [ <ulink linkID=\"2828252\" linkType=\"Reference\"> 2828252 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3510",
              "name": "Pulmonary artery hypertension"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Priority Review",
            "startDate": "13-Jun-2018",
            "endDate": "24-Apr-2024",
            "statusDate": "30-Jun-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "92%",
            "timeToRegistration": "0.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Jun-2018",
                "endDate": "25-Jan-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "25-Jan-2021",
                "endDate": "30-Jun-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Jun-2023",
                "endDate": "25-Mar-2024",
                "successPercentage": "92%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Mar-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-Jan-2024",
                "predictedDateU50": "24-Apr-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "10-Oct-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, positive topline data were reported from the phase III STELLAR trial demonstrating the primary endpoint to have been met with a significant improvement in the 6-min walk distance at 24 weeks [ <ulink linkID=\"2748942\" linkType=\"Reference\"> 2748942 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2023, new data from a phase III trial (NCT04576988; STELLAR) for the treatment of pulmonary arterial hypertension were expected to present in March 2023 [ <ulink linkID=\"2828252\" linkType=\"Reference\"> 2828252 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "30-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "By June 2023, Merck submitted a BLA to the US FDA for sotatercept for the treatment of adults with PAH [ <ulink linkID=\"3030109\" linkType=\"Reference\"> 3030109 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Priority Review",
                "status": "Granted",
                "milestoneDate": "28-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, the US FDA accepted priority review for BLA based on data from phase III STELLAR trial and set a Prescription Drug User Fee Act (PDUFA) date as March 26, 2024 [ <ulink linkID=\"3271010\" linkType=\"Reference\"> 3271010 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "26-Mar-2024",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, the US FDA accepted priority review for BLA based on data from phase III STELLAR trial and set a Prescription Drug User Fee Act (PDUFA) date as March 26, 2024 [ <ulink linkID=\"3271010\" linkType=\"Reference\"> 3271010 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3511",
              "name": "Left heart disease pulmonary hypertension"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Dec-2021",
            "endDate": "21-Jan-2030",
            "statusDate": "29-Dec-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "7%",
            "timeToRegistration": "6.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "29-Dec-2021",
                "endDate": "19-May-2026",
                "successPercentage": "46%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "19-May-2026",
                "endDate": "15-Feb-2029",
                "successPercentage": "17%",
                "predictedDateL50": "19-Sep-2025",
                "predictedDateU50": "31-Oct-2026",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Feb-2029",
                "endDate": "15-Dec-2029",
                "successPercentage": "88%",
                "predictedDateL50": "21-Dec-2027",
                "predictedDateU50": "31-Jul-2029",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-Dec-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "03-Sep-2029",
                "predictedDateU50": "21-Jan-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "19-May-2026",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, a phase II trial (NCT04945460; CADENCE) for Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) Due to Heart Failure With Preserved Ejection Fraction (HFpEF) was expected to complete in May 2026 [ <ulink linkID=\"3314863\" linkType=\"Reference\"> 3314863 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3511",
              "name": "Left heart disease pulmonary hypertension"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Dec-2021",
            "endDate": "19-Mar-2030",
            "statusDate": "29-Dec-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "8%",
            "timeToRegistration": "6.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "29-Dec-2021",
                "endDate": "19-May-2026",
                "successPercentage": "48%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "19-May-2026",
                "endDate": "15-Feb-2029",
                "successPercentage": "18%",
                "predictedDateL50": "19-Sep-2025",
                "predictedDateU50": "31-Oct-2026",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Feb-2029",
                "endDate": "09-Feb-2030",
                "successPercentage": "87%",
                "predictedDateL50": "21-Dec-2027",
                "predictedDateU50": "31-Jul-2029",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Feb-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Oct-2029",
                "predictedDateU50": "19-Mar-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "19-May-2026",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, a phase II trial (NCT04945460; CADENCE) for Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) Due to Heart Failure With Preserved Ejection Fraction (HFpEF) was expected to complete in May 2026 [ <ulink linkID=\"3314863\" linkType=\"Reference\"> 3314863 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "70667",
        "displayName": "pembrolizumab",
        "drugPrograms": [
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Jan-2016",
            "endDate": "24-May-2022",
            "statusDate": "24-May-2022",
            "phaseHighestStatus": "Reg",
            "probabilityOfSuccess": null,
            "timeToRegistration": "-1.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "27-Jan-2016",
                "endDate": "03-Mar-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "03-Mar-2017",
                "endDate": "25-Apr-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Apr-2022",
                "endDate": "24-May-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "24-May-2022",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "29-Jul-2019",
                "milestoneExtendedDate": "",
                "notes": "In July 2019, it was reported that the phase III KEYNOTE-522 trial met one of the dual-primary endpoints of pathological complete response. Based on an interim analysis from the independent Data Monitoring Committee, the trial was planned to continue without changes to evaluate the other dual-primary endpoint of event-free survival. No new safety signals were found [<ulink linkType=\"Reference\" linkID=\"2177999\">2177999</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "29-Sep-2019",
                "milestoneExtendedDate": "",
                "notes": "In September 2019, interim data of a phase III trial were presented [<ulink linkType=\"Reference\" linkID=\"2199236\">2199236</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "29-Sep-2019",
                "milestoneExtendedDate": "",
                "notes": "In September 2019, primary endpoints of a phase III trial (pathological complete response and event free survival) were met [<ulink linkType=\"Reference\" linkID=\"2199236\">2199236</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In February 2019, data from a phase III trial (KEYNOTE 522) in non-metastatic triple negative breast cancer were expected in 2019 [<ulink linkType=\"Reference\" linkID=\"2116422\">2116422</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In April 2022, approval for pembrolizumab in combination with chemotherapy for the neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence, based on KEYNOTE-522, was expected in 2Q22 [ <ulink linkID=\"2656577\" linkType=\"Reference\">  2656577 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In April 2022, approval for pembrolizumab in combination with chemotherapy for the neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence, based on KEYNOTE-522, was expected in 2Q22 [ <ulink linkID=\"2656577\" linkType=\"Reference\">  2656577 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "CHMP Opinion",
                "status": "Positive Opinion",
                "milestoneDate": "25-Apr-2022",
                "milestoneExtendedDate": "",
                "notes": "In April 2022, the EMA's CHMP recommended approval for pembrolizumab in combination with chemotherapy for the neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence, based on KEYNOTE-522; at that time, a final decision was expected in 2Q22 [ <ulink linkID=\"2656577\" linkType=\"Reference\">  2656577 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU",
              " EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Breakthrough Therapy",
            "startDate": "03-Mar-2017",
            "endDate": "",
            "statusDate": "30-Jul-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "03-Mar-2017",
                "endDate": "30-Jul-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Jul-2020",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "127",
              "name": "Stomach tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Jul-2020",
            "endDate": "29-Jan-2027",
            "statusDate": "15-Jul-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "18%",
            "timeToRegistration": "3.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "15-Jul-2020",
                "endDate": "31-Oct-2025",
                "successPercentage": "19%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Oct-2025",
                "endDate": "01-Dec-2026",
                "successPercentage": "95%",
                "predictedDateL50": "14-Apr-2025",
                "predictedDateU50": "12-Mar-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Dec-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Jul-2026",
                "predictedDateU50": "29-Jan-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "22-Jul-2020",
                "milestoneExtendedDate": "",
                "notes": "In July 2020, an implied clinical trial approval of the drug was obtained for the treatment of gastric or gastroesophageal junction adenocarcinoma in China [  <ulink linkID=\"2294364\" linkType=\"Reference\">   2294364  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "28-Jun-2024",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, the phase III KEYNOTE-585 trial (NCT03221426) of pembrolizumab in the neoadjuvant/adjuvant treatment of previously untreated localized gastric or gastroesophageal junction adenocarcinoma was expected to complete in June 2024 [ <ulink linkID=\"1991951\" linkType=\"Reference\">  1991951 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Oct-2025",
                "milestoneExtendedDate": "",
                "notes": "In July 2021, the phase III KEYNOTE-585-China Extension trial (NCT04882241) of pembrolizumab in the neoadjuvant/adjuvant treatment of previously untreated localized gastric or gastroesophageal junction adenocarcinoma was expected to complete in October 2025 [ <ulink linkID=\"2672372\" linkType=\"Reference\">  2672372 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "127",
              "name": "Stomach tumor"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Oct-2017",
            "endDate": "11-Jun-2024",
            "statusDate": "21-Jul-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Oct-2017",
                "endDate": "21-Jul-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Jul-2023",
                "endDate": "12-May-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-May-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-Feb-2024",
                "predictedDateU50": "11-Jun-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Mar-2023",
                "milestoneExtendedDate": "31-Mar-2023",
                "notes": "In October 2019, a phase I/II trial (NCT04060342) in combination with GB-1275 in advanced solid tumors was expected to complete in March 2023 [ <ulink linkID=\"2185368\" linkType=\"Reference\">  2185368 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "127",
              "name": "Stomach tumor"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Oct-2017",
            "endDate": "",
            "statusDate": "09-Oct-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Oct-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "127",
              "name": "Stomach tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Oct-2017",
            "endDate": "",
            "statusDate": "09-Oct-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Oct-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "127",
              "name": "Stomach tumor"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Oct-2017",
            "endDate": "26-Dec-2025",
            "statusDate": "09-Oct-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "17%",
            "timeToRegistration": "2.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Oct-2017",
                "endDate": "29-Nov-2024",
                "successPercentage": "18%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Nov-2024",
                "endDate": "16-Nov-2025",
                "successPercentage": "95%",
                "predictedDateL50": "18-Mar-2024",
                "predictedDateU50": "29-May-2025",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "16-Nov-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Jul-2025",
                "predictedDateU50": "26-Dec-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "28-Jun-2024",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, the phase III KEYNOTE-585 trial (NCT03221426) of pembrolizumab in the neoadjuvant/adjuvant treatment of previously untreated localized gastric or gastroesophageal junction adenocarcinoma was expected to complete in June 2024 [ <ulink linkID=\"1991951\" linkType=\"Reference\">  1991951 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "127",
              "name": "Stomach tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "31-Jan-2017",
            "endDate": "05-Dec-2025",
            "statusDate": "09-Oct-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "24%",
            "timeToRegistration": "1.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Jan-2017",
                "endDate": "09-Oct-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "09-Oct-2017",
                "endDate": "03-Feb-2025",
                "successPercentage": "25%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Feb-2025",
                "endDate": "03-Nov-2025",
                "successPercentage": "95%",
                "predictedDateL50": "02-Apr-2024",
                "predictedDateU50": "10-Jun-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "03-Nov-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Aug-2025",
                "predictedDateU50": "05-Dec-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Mar-2023",
                "milestoneExtendedDate": "31-Mar-2023",
                "notes": "In October 2019, a phase I/II trial (NCT04060342) in combination with GB-1275 in advanced solid tumors was expected to complete in March 2023 [ <ulink linkID=\"2185368\" linkType=\"Reference\">  2185368 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "28-Jun-2024",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, the phase III KEYNOTE-585 trial (NCT03221426) of pembrolizumab in the neoadjuvant/adjuvant treatment of previously untreated localized gastric or gastroesophageal junction adenocarcinoma was expected to complete in June 2024 [ <ulink linkID=\"1991951\" linkType=\"Reference\">  1991951 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "131",
              "name": "Gastrointestinal tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Mar-2017",
            "endDate": "28-Apr-2028",
            "statusDate": "09-Dec-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "30-Mar-2017",
                "endDate": "09-Dec-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "09-Dec-2021",
                "endDate": "29-Sep-2024",
                "successPercentage": "18%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "29-Sep-2024",
                "endDate": "29-Jun-2027",
                "successPercentage": "13%",
                "predictedDateL50": "02-Mar-2024",
                "predictedDateU50": "17-Feb-2025",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Jun-2027",
                "endDate": "28-Mar-2028",
                "successPercentage": "95%",
                "predictedDateL50": "03-May-2026",
                "predictedDateU50": "12-Dec-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "28-Mar-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-Dec-2027",
                "predictedDateU50": "28-Apr-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "23-Jan-2020",
                "milestoneExtendedDate": "",
                "notes": "In January 2020, positive data were reported for the phase Ib trial (NCT03095781) in patients with advanced gastrointestinal malignancies which showed that the trial met its primary endpoint; the recommended phase II dose (primary endpoint) was determined to be XL-888 (90 mg, biw) + pembrolizumab (200 mg, q3w) [<ulink linkType=\"Reference\" linkID=\"2242996\">2242996</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "23-Jan-2020",
                "milestoneExtendedDate": "",
                "notes": "In January 2020, positive interim data of phase I trial (NCT03095781) in patients with advanced gastrointestinal malignancies were presented which showed the trial met its primary endpoint [<ulink linkType=\"Reference\" linkID=\"2242996\">2242996</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "29-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a phase II trial (NCT05104567) in patients with metastatic gastrointestinal cancer was expected to complete in August  2023 [  <ulink linkID=\"2589126\" linkType=\"Reference\">  2589126 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "194",
              "name": "Sarcoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (FR)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Mar-2015",
            "endDate": "",
            "statusDate": "31-Mar-2015",
            "phaseHighestStatus": "Repositioned",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Mar-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "FR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "194",
              "name": "Sarcoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Mar-2015",
            "endDate": "15-Jul-2027",
            "statusDate": "11-Mar-2015",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "17%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-Mar-2015",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "15-Sep-2026",
                "successPercentage": "19%",
                "predictedDateL50": "24-Jan-2023",
                "predictedDateU50": "19-Jun-2024",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Sep-2026",
                "endDate": "13-Jun-2027",
                "successPercentage": "95%",
                "predictedDateL50": "15-Jul-2025",
                "predictedDateU50": "08-Mar-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Mar-2027",
                "predictedDateU50": "15-Jul-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In February 2019, a US phase I/II trial was planned for later in 2019 to evaluate pembrolizumab with Torque’s TRQ-1501 as a single agent and in combination in standard-of-care relapsed or refractory sarcoma [<ulink linkType=\"Reference\" linkID=\"2121208\">2121208</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "01-Jun-2019",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, final results of a phase II study were presented [<ulink linkType=\"Reference\" linkID=\"2155812\">2155812</ulink>].  </para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "03-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, positive results of a phase II trial (NCT04784247) of pembrolizumab in combination with lenvatinib in 44 patients were presented. The best ORR by 27 weeks in cohort A (LMS) included SD was 60%; in cohort B (UPS) included PR (33.3%) and SD (50%); in cohort C (overall/ angio/ EHE) included SD (87.5%/ 100%/ 50%); in cohort D (overall/ SS/ MPNST) included PR (33.3% each) and SD (44.4%/ 50%, 33.3.%); in cohort E (overall/ chondro/ osteo) included PR (10%/ 0%/ 16.6%) and SD (70%/ 75%/ 66.7%) respectively [ <ulink linkID=\"3020547\" linkType=\"Reference\"> 3020547 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "203",
              "name": "Lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Mar-2015",
            "endDate": "",
            "statusDate": "07-Jun-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Mar-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "249",
              "name": "Pancreas tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe (GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Dec-2015",
            "endDate": "",
            "statusDate": "04-Jul-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Dec-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "249",
              "name": "Pancreas tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Dec-2015",
            "endDate": "",
            "statusDate": "08-Jul-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Dec-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "307",
              "name": "Squamous cell carcinoma"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "26-Apr-2013",
            "endDate": "",
            "statusDate": "28-Jun-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "26-Apr-2013",
                "endDate": "25-Aug-2014",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "25-Aug-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "307",
              "name": "Squamous cell carcinoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Nov-2014",
            "endDate": "",
            "statusDate": "28-Jun-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "17-Nov-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "307",
              "name": "Squamous cell carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Aug-2014",
            "endDate": "",
            "statusDate": "28-Jun-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "25-Aug-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (DE, IT)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Paediatric Investigation Plan",
            "startDate": "07-Dec-2019",
            "endDate": "11-Jul-2029",
            "statusDate": "07-Dec-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "5.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "07-Dec-2019",
                "endDate": "18-Dec-2025",
                "successPercentage": "25%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "18-Dec-2025",
                "endDate": "10-Jul-2028",
                "successPercentage": "12%",
                "predictedDateL50": "17-May-2025",
                "predictedDateU50": "09-Jul-2026",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Jul-2028",
                "endDate": "06-Jun-2029",
                "successPercentage": "91%",
                "predictedDateL50": "01-Jun-2027",
                "predictedDateU50": "23-Nov-2028",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-Jun-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "21-Feb-2029",
                "predictedDateU50": "11-Jul-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "18-Dec-2025",
                "milestoneExtendedDate": "",
                "notes": "In July 2018, it was reported that a phase I/II study was expected to complete in December 18, 2025[<ulink linkType=\"Reference\" linkID=\"2058244\">2058244</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "DE",
              " IT"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Nov-2013",
            "endDate": "15-May-2029",
            "statusDate": "01-Nov-2017",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "5.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "22-Nov-2013",
                "endDate": "01-Nov-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "01-Nov-2017",
                "endDate": "18-Dec-2025",
                "successPercentage": "23%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "18-Dec-2025",
                "endDate": "10-Jul-2028",
                "successPercentage": "11%",
                "predictedDateL50": "05-May-2025",
                "predictedDateU50": "18-Jul-2026",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Jul-2028",
                "endDate": "15-Apr-2029",
                "successPercentage": "92%",
                "predictedDateL50": "01-Jun-2027",
                "predictedDateU50": "23-Nov-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-Apr-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Jan-2029",
                "predictedDateU50": "15-May-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "18-Dec-2025",
                "milestoneExtendedDate": "",
                "notes": "In July 2018, it was reported that a phase I/II study was expected to complete in December 18, 2025[<ulink linkType=\"Reference\" linkID=\"2058244\">2058244</ulink>].\n</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "427",
              "name": "Uterine cervix tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Jul-2020",
            "endDate": "02-Nov-2025",
            "statusDate": "22-Jul-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "34%",
            "timeToRegistration": "1.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "22-Jul-2020",
                "endDate": "19-Jul-2024",
                "successPercentage": "36%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "19-Jul-2024",
                "endDate": "01-Sep-2025",
                "successPercentage": "95%",
                "predictedDateL50": "20-Jan-2024",
                "predictedDateU50": "07-Nov-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Sep-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Apr-2025",
                "predictedDateU50": "02-Nov-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "427",
              "name": "Uterine cervix tumor"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "27-Sep-2022",
            "statusDate": "27-Sep-2022",
            "phaseHighestStatus": "Reg",
            "probabilityOfSuccess": null,
            "timeToRegistration": "-1.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "25-Oct-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "25-Oct-2018",
                "endDate": "22-Oct-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Oct-2021",
                "endDate": "27-Sep-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Sep-2022",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "JP",
              " JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "623",
              "name": "Head and neck tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Sep-2020",
            "endDate": "04-Oct-2025",
            "statusDate": "10-Sep-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "53%",
            "timeToRegistration": "1.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "10-Sep-2020",
                "endDate": "29-Jul-2024",
                "successPercentage": "56%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Jul-2024",
                "endDate": "13-Aug-2025",
                "successPercentage": "95%",
                "predictedDateL50": "25-Jan-2024",
                "predictedDateU50": "09-Dec-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Aug-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "08-Apr-2025",
                "predictedDateU50": "04-Oct-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "623",
              "name": "Head and neck tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Jun-2016",
            "endDate": "19-Nov-2026",
            "statusDate": "17-Dec-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "50%",
            "timeToRegistration": "2.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "15-Jun-2016",
                "endDate": "17-Dec-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "17-Dec-2018",
                "endDate": "21-Jan-2026",
                "successPercentage": "53%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Jan-2026",
                "endDate": "17-Oct-2026",
                "successPercentage": "95%",
                "predictedDateL50": "15-Aug-2025",
                "predictedDateU50": "02-Jul-2026",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Oct-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-Jul-2026",
                "predictedDateU50": "19-Nov-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In February 2019, a US phase I/II trial was planned for later in 2019 to evaluate pembrolizumab with Torque’s TRQ-1501 as a single agent and in combination in anti programmed cell death protein-1/programmed death-ligand 1 inhibitor relapsed or refractory head and neck cancer [<ulink linkType=\"Reference\" linkID=\"2121208\">2121208</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-May-2020",
                "milestoneExtendedDate": "29-May-2020",
                "notes": "In February 2020, a randomized, parallel, double phase III study (NCT04199104; 7902-010; MK-7902-010; LEAP-10 ) which evaluated the efficacy and safety of pembrolizumab with or without lenvatinib as first line  intervention began in patients with recurrent or metastatic head and neck squamous cell carcinoma. At that time, the trial was estimated to complete in April 2024 [<ulink linkType=\"Reference\" linkID=\"2291708\">2291708</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Jul-2021",
                "notes": "In October 2019, the phase II trial (NCT02641093) assessing adjuvant combined cisplatin and radiation with pembrolizumab in resected head and neck squamous cell carcinoma was expected to complete in July 2021 [<ulink linkType=\"Reference\" linkID=\"2209835\">2209835</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "21-Jan-2026",
                "milestoneExtendedDate": "",
                "notes": "In January 2019, the phase III trial for head and neck neoplasms was expected to be completed in January 2026 [<ulink linkType=\"Reference\" linkID=\"2111154\">2111154</ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "623",
              "name": "Head and neck tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Dec-2018",
            "endDate": "08-Feb-2027",
            "statusDate": "17-Dec-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "50%",
            "timeToRegistration": "3.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "17-Dec-2018",
                "endDate": "21-Jan-2026",
                "successPercentage": "53%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Jan-2026",
                "endDate": "29-Dec-2026",
                "successPercentage": "95%",
                "predictedDateL50": "25-Aug-2025",
                "predictedDateU50": "23-Jun-2026",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-Dec-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Sep-2026",
                "predictedDateU50": "08-Feb-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-May-2020",
                "milestoneExtendedDate": "29-May-2020",
                "notes": "In February 2020, a randomized, parallel, double phase III study (NCT04199104; 7902-010; MK-7902-010; LEAP-10 ) which evaluated the efficacy and safety of pembrolizumab with or without lenvatinib as first line  intervention began in patients with recurrent or metastatic head and neck squamous cell carcinoma. At that time, the trial was estimated to complete in April 2024 [<ulink linkType=\"Reference\" linkID=\"2291708\">2291708</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "21-Jan-2026",
                "milestoneExtendedDate": "",
                "notes": "In January 2019, the phase III trial for head and neck neoplasms was expected to be completed in January 2026 [<ulink linkType=\"Reference\" linkID=\"2111154\">2111154</ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "740",
              "name": "Uterus tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-Dec-2021",
            "endDate": "20-Apr-2028",
            "statusDate": "07-Dec-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "07-Dec-2021",
                "endDate": "18-Sep-2024",
                "successPercentage": "24%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "18-Sep-2024",
                "endDate": "18-Jun-2027",
                "successPercentage": "11%",
                "predictedDateL50": "28-Feb-2024",
                "predictedDateU50": "01-Feb-2025",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "18-Jun-2027",
                "endDate": "20-Mar-2028",
                "successPercentage": "95%",
                "predictedDateL50": "22-Apr-2026",
                "predictedDateU50": "01-Dec-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-Mar-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Dec-2027",
                "predictedDateU50": "20-Apr-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "23-Dec-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2022, a phase II trial (NCT05147558) in patients with advanced uterine carcinosarcoma was expected to complete in December 2023 [ <ulink linkID=\"2595611\" linkType=\"Reference\">  2595611 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "763",
              "name": "Nerve tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe (NO)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-Jun-2016",
            "endDate": "",
            "statusDate": "07-Jun-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "07-Jun-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "NO"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "799",
              "name": "Ovary tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2016",
            "endDate": "10-Jul-2028",
            "statusDate": "13-Dec-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "26%",
            "timeToRegistration": "4.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Sep-2016",
                "endDate": "13-Dec-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "13-Dec-2021",
                "endDate": "31-Aug-2027",
                "successPercentage": "28%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Aug-2027",
                "endDate": "10-Jun-2028",
                "successPercentage": "92%",
                "predictedDateL50": "08-Feb-2027",
                "predictedDateU50": "15-Dec-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Jun-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "03-Mar-2028",
                "predictedDateU50": "10-Jul-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "20-Nov-2018",
                "milestoneExtendedDate": "",
                "notes": "In November 2018, a phase I/II trial was expected to initiate on November 20, 2018 [<ulink linkType=\"Reference\" linkID=\"2094214\">2094214</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "13-Jun-2019",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, positive efficacy data from the integrated phase I and II (KEYNOTE-162; TOPACIO) ovarian carcinoma population (60 of 62 evaluable patients) of niraparib in combination with pembrolizumab were published showing an ORR of 18% and a disease control rate of 65%, including 3 (5%) patients with confirmed complete responses, 8 (13%) patients with confirmed partial responses, 28 (47%) patients with stable disease, and 20 (33%) patients with progressive disease [<ulink linkType=\"Reference\" linkID=\"2164165\">2164165</ulink>], [<ulink linkType=\"Reference\" linkID=\"2164280\">2164280</ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In November 2018, a phase I/II trial was expected to complete on November 20, 2023 [<ulink linkType=\"Reference\" linkID=\"2094214\">2094214</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Aug-2027",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a phase III (NCT05116189) trial was expected to complete on August  2027 [ <ulink linkID=\"2590031\" linkType=\"Reference\">  2590031 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "936",
              "name": "Kaposis sarcoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (FR)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Jul-2018",
            "endDate": "23-Jul-2027",
            "statusDate": "01-Jul-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Jul-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "51%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "31-Jul-2026",
                "successPercentage": "8%",
                "predictedDateL50": "14-Feb-2023",
                "predictedDateU50": "20-May-2024",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Jul-2026",
                "endDate": "11-Jun-2027",
                "successPercentage": "93%",
                "predictedDateL50": "14-Jun-2025",
                "predictedDateU50": "23-Dec-2026",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Mar-2027",
                "predictedDateU50": "23-Jul-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "19-Aug-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, positive data for the phase II trial (NCT03469804) for the first-line treatment of patients with classic and endemic Kaposi’s sarcoma were reported which showed that the trial met its primary endpoint. Pembrolizumab treatment was effective (best overall response rate (primary endpoint) above 30%) and showed an acceptable safety profile in patients with classic and endemic Kaposi’s sarcoma [<ulink linkType=\"Reference\" linkID=\"2325042\">2325042</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "19-Aug-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, topline data for the phase II trial (NCT03469804) for the first-line treatment of patients with classic and endemic Kaposi’s sarcoma were reported [<ulink linkType=\"Reference\" linkID=\"2325042\">2325042</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "FR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "989",
              "name": "Colorectal tumor"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-May-2017",
            "endDate": "",
            "statusDate": "05-May-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "05-May-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1011",
              "name": "Esophagus tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Jul-2020",
            "endDate": "26-Nov-2025",
            "statusDate": "15-Jul-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "49%",
            "timeToRegistration": "1.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "15-Jul-2020",
                "endDate": "29-Aug-2024",
                "successPercentage": "52%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Aug-2024",
                "endDate": "29-Sep-2025",
                "successPercentage": "95%",
                "predictedDateL50": "24-Jan-2024",
                "predictedDateU50": "07-Jan-2025",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-Sep-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-May-2025",
                "predictedDateU50": "26-Nov-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "28-Jun-2024",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, the phase III KEYNOTE-585 trial (NCT03221426) of pembrolizumab in the neoadjuvant/adjuvant treatment of previously untreated localized gastric or gastroesophageal junction adenocarcinoma was expected to complete in June 2024 [ <ulink linkID=\"1991951\" linkType=\"Reference\">  1991951 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1011",
              "name": "Esophagus tumor"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Oct-2017",
            "endDate": "17-Sep-2025",
            "statusDate": "09-Oct-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "44%",
            "timeToRegistration": "1.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Oct-2017",
                "endDate": "04-Nov-2024",
                "successPercentage": "46%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "04-Nov-2024",
                "endDate": "18-Aug-2025",
                "successPercentage": "95%",
                "predictedDateL50": "05-Mar-2024",
                "predictedDateU50": "01-Apr-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "18-Aug-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "08-May-2025",
                "predictedDateU50": "17-Sep-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "28-Jun-2024",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, the phase III KEYNOTE-585 trial (NCT03221426) of pembrolizumab in the neoadjuvant/adjuvant treatment of previously untreated localized gastric or gastroesophageal junction adenocarcinoma was expected to complete in June 2024 [ <ulink linkID=\"1991951\" linkType=\"Reference\">  1991951 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1011",
              "name": "Esophagus tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Oct-2017",
            "endDate": "22-Jul-2025",
            "statusDate": "09-Oct-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "48%",
            "timeToRegistration": "1.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Oct-2017",
                "endDate": "12-Sep-2024",
                "successPercentage": "50%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-Sep-2024",
                "endDate": "22-Jun-2025",
                "successPercentage": "95%",
                "predictedDateL50": "05-Feb-2024",
                "predictedDateU50": "02-Dec-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Jun-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Mar-2025",
                "predictedDateU50": "22-Jul-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "28-Feb-2020",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, a phase III trial (NCT04210115) in patients with esophageal carcinoma receiving concurrent definitive chemoradiotherapy was expected to end in February 2026 [<ulink linkType=\"Reference\" linkID=\"2274907\">2274907</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "28-Jun-2024",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, the phase III KEYNOTE-585 trial (NCT03221426) of pembrolizumab in the neoadjuvant/adjuvant treatment of previously untreated localized gastric or gastroesophageal junction adenocarcinoma was expected to complete in June 2024 [ <ulink linkID=\"1991951\" linkType=\"Reference\">  1991951 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1011",
              "name": "Esophagus tumor"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Oct-2017",
            "endDate": "16-Jan-2026",
            "statusDate": "09-Oct-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "47%",
            "timeToRegistration": "2.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Oct-2017",
                "endDate": "20-Dec-2024",
                "successPercentage": "49%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-Dec-2024",
                "endDate": "05-Dec-2025",
                "successPercentage": "95%",
                "predictedDateL50": "22-Mar-2024",
                "predictedDateU50": "29-May-2025",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Dec-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "12-Aug-2025",
                "predictedDateU50": "16-Jan-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "28-Jun-2024",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, the phase III KEYNOTE-585 trial (NCT03221426) of pembrolizumab in the neoadjuvant/adjuvant treatment of previously untreated localized gastric or gastroesophageal junction adenocarcinoma was expected to complete in June 2024 [ <ulink linkID=\"1991951\" linkType=\"Reference\">  1991951 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1011",
              "name": "Esophagus tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "09-Oct-2017",
            "endDate": "07-Dec-2025",
            "statusDate": "09-Oct-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "56%",
            "timeToRegistration": "1.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Oct-2017",
                "endDate": "05-Feb-2025",
                "successPercentage": "59%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Feb-2025",
                "endDate": "04-Nov-2025",
                "successPercentage": "95%",
                "predictedDateL50": "03-Apr-2024",
                "predictedDateU50": "10-Jun-2025",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Nov-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "03-Aug-2025",
                "predictedDateU50": "07-Dec-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "28-Feb-2020",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, a phase III trial (NCT04210115) in patients with esophageal carcinoma receiving concurrent definitive chemoradiotherapy was expected to end in February 2026 [<ulink linkType=\"Reference\" linkID=\"2274907\">2274907</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "28-Jun-2024",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, the phase III KEYNOTE-585 trial (NCT03221426) of pembrolizumab in the neoadjuvant/adjuvant treatment of previously untreated localized gastric or gastroesophageal junction adenocarcinoma was expected to complete in June 2024 [ <ulink linkID=\"1991951\" linkType=\"Reference\">  1991951 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1011",
              "name": "Esophagus tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Oct-2017",
            "endDate": "07-Mar-2026",
            "statusDate": "09-Oct-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "45%",
            "timeToRegistration": "2.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Oct-2017",
                "endDate": "03-Feb-2025",
                "successPercentage": "47%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Feb-2025",
                "endDate": "27-Jan-2026",
                "successPercentage": "95%",
                "predictedDateL50": "02-Apr-2024",
                "predictedDateU50": "10-Jun-2025",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Jan-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-Sep-2025",
                "predictedDateU50": "07-Mar-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "28-Feb-2020",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, a phase III trial (NCT04210115) in patients with esophageal carcinoma receiving concurrent definitive chemoradiotherapy was expected to end in February 2026 [<ulink linkType=\"Reference\" linkID=\"2274907\">2274907</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "28-Jun-2024",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, the phase III KEYNOTE-585 trial (NCT03221426) of pembrolizumab in the neoadjuvant/adjuvant treatment of previously untreated localized gastric or gastroesophageal junction adenocarcinoma was expected to complete in June 2024 [ <ulink linkID=\"1991951\" linkType=\"Reference\">  1991951 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1115",
              "name": "Mycosis fungoides"
            },
            "country": {
              "id": "EU",
              "name": "Europe (GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Jan-2019",
            "endDate": "01-Oct-2028",
            "statusDate": "15-Jan-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "15-Jan-2019",
                "endDate": "25-Jan-2025",
                "successPercentage": "25%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "25-Jan-2025",
                "endDate": "02-Oct-2027",
                "successPercentage": "23%",
                "predictedDateL50": "16-Mar-2024",
                "predictedDateU50": "26-Jul-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-Oct-2027",
                "endDate": "27-Aug-2028",
                "successPercentage": "95%",
                "predictedDateL50": "12-Aug-2026",
                "predictedDateU50": "04-Mar-2028",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Aug-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-May-2028",
                "predictedDateU50": "01-Oct-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2024",
                "milestoneExtendedDate": "31-Jul-2024",
                "notes": "In January 2019, a phase II was expected to complete in July 2024 [<ulink linkType=\"Reference\" linkID=\"2116222\">2116222</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1128",
              "name": "Neuroendocrine tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Dec-2015",
            "endDate": "",
            "statusDate": "18-Oct-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Dec-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1134",
              "name": "Thyroid tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "",
            "statusDate": "28-Nov-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "18-Dec-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "18-Dec-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1240",
              "name": "Mesothelioma"
            },
            "country": {
              "id": "US",
              "name": "US, US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "23-Jul-2026",
            "statusDate": "28-Jul-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "26%",
            "timeToRegistration": "2.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "18-Mar-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "18-Mar-2015",
                "endDate": "28-Jul-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "28-Jul-2022",
                "endDate": "21-Sep-2025",
                "successPercentage": "27%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Sep-2025",
                "endDate": "20-Jun-2026",
                "successPercentage": "95%",
                "predictedDateL50": "12-Dec-2024",
                "predictedDateU50": "13-Jan-2026",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-Jun-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Mar-2026",
                "predictedDateU50": "23-Jul-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US",
              " US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1240",
              "name": "Mesothelioma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "",
            "statusDate": "12-Sep-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "18-Mar-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "18-Mar-2015",
                "endDate": "12-Sep-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "12-Sep-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1261",
              "name": "Small-cell lung cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Nov-2020",
            "endDate": "31-Aug-2025",
            "statusDate": "10-Nov-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "37%",
            "timeToRegistration": "1.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "10-Nov-2020",
                "endDate": "16-Jun-2024",
                "successPercentage": "39%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-Jun-2024",
                "endDate": "09-Jul-2025",
                "successPercentage": "95%",
                "predictedDateL50": "15-Jan-2024",
                "predictedDateU50": "22-Sep-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Jul-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Mar-2025",
                "predictedDateU50": "31-Aug-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "24-Feb-2021",
                "milestoneExtendedDate": "",
                "notes": "In February 2021, an implied trial approval was granted for small cell lung cancer in limited stage [<ulink linkType=\"Reference\" linkID=\"2399834\">2399834</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1261",
              "name": "Small-cell lung cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "26-Apr-2013",
            "endDate": "",
            "statusDate": "01-Nov-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "26-Apr-2013",
                "endDate": "01-Nov-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Nov-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1261",
              "name": "Small-cell lung cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "",
            "statusDate": "06-Apr-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "18-Dec-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "18-Dec-2015",
                "endDate": "06-Apr-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "06-Apr-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1261",
              "name": "Small-cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug, Priority Review, Accelerated Approval",
            "startDate": "17-Feb-2014",
            "endDate": "",
            "statusDate": "02-May-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "18-Dec-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "18-Dec-2015",
                "endDate": "02-May-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-May-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1261",
              "name": "Small-cell lung cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "",
            "statusDate": "02-May-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "18-Dec-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "18-Dec-2015",
                "endDate": "02-May-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-May-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1262",
              "name": "Non-small-cell lung cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe (EU, GB, NO)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Nov-2015",
            "endDate": "09-Jan-2024",
            "statusDate": "28-Jul-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "15-Nov-2015",
                "endDate": "28-Jul-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "28-Jul-2022",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Dec-2023",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Nov-2023",
                "predictedDateU50": "09-Jan-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "sNDA/sBLA Filing",
                "status": "Filed",
                "milestoneDate": "28-Jul-2022",
                "milestoneExtendedDate": "",
                "notes": "By July 2022, an application had been submitted to the EMA for the treatment of adjuvant early-stage NSCLC, presumably based on KEYNOTE-091 [ <ulink linkID=\"2710889\" linkType=\"Reference\">  2710889 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "CHMP Opinion",
                "status": "Positive Opinion",
                "milestoneDate": "14-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, the EMA's CHMP adopted a positive opinion recommending approval for the adjuvant treatment of adult patients with NSCLC who are at high risk of recurrence following complete resection and platinum-based chemotherapy, based on data from the KEYNOTE-091 trial [ <ulink linkID=\"3197894\" linkType=\"Reference\"> 3197894 </ulink>], [ <ulink linkID=\"3197125\" linkType=\"Reference\"> 3197125 </ulink>]. <b> </b></para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In September 2023, the EMA's CHMP adopted a positive opinion recommending approval for the adjuvant treatment of adult patients with NSCLC who are at high risk of recurrence following complete resection and platinum-based chemotherapy, based on data from the KEYNOTE-091 trial. At that time, it was reported that the CHMP’s recommendation would be reviewed by the EC for MAA in the EU and the final decision was expected in 4Q23 [ <ulink linkID=\"3197894\" linkType=\"Reference\"> 3197894 </ulink>], [ <ulink linkID=\"3197125\" linkType=\"Reference\"> 3197125 </ulink>]. <b> </b></para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU",
              " GB",
              " NO"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1262",
              "name": "Non-small-cell lung cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "24-Apr-2018",
            "endDate": "01-Jul-2025",
            "statusDate": "07-May-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "82%",
            "timeToRegistration": "1.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "24-Apr-2018",
                "endDate": "30-Aug-2024",
                "successPercentage": "86%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Aug-2024",
                "endDate": "29-May-2025",
                "successPercentage": "95%",
                "predictedDateL50": "21-Jan-2024",
                "predictedDateU50": "18-Nov-2024",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-May-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Feb-2025",
                "predictedDateU50": "01-Jul-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "21-Jul-2018",
                "milestoneExtendedDate": "",
                "notes": "In July 2018, based on the results from interim analysis of post-marketing surveillance (Japan), high tumor proportion score (>/= 50%) was noted in 99% of first-line treatment and 59% of >/=second-line treatment treatment patients [<ulink linkType=\"Reference\" linkID=\"2121342\">2121342</ulink>].\n</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1262",
              "name": "Non-small-cell lung cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "24-Apr-2018",
            "endDate": "25-Apr-2025",
            "statusDate": "07-May-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "82%",
            "timeToRegistration": "1.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "24-Apr-2018",
                "endDate": "25-Jun-2024",
                "successPercentage": "86%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Jun-2024",
                "endDate": "23-Mar-2025",
                "successPercentage": "95%",
                "predictedDateL50": "02-Jan-2024",
                "predictedDateU50": "09-Sep-2024",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Mar-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "21-Dec-2024",
                "predictedDateU50": "25-Apr-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1272",
              "name": "Myelodysplastic syndrome"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Nov-2013",
            "endDate": "17-Jan-2028",
            "statusDate": "06-Nov-2017",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "22-Nov-2013",
                "endDate": "06-Nov-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "06-Nov-2017",
                "endDate": "13-Aug-2024",
                "successPercentage": "19%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "13-Aug-2024",
                "endDate": "25-Mar-2027",
                "successPercentage": "13%",
                "predictedDateL50": "11-Feb-2024",
                "predictedDateU50": "22-Feb-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Mar-2027",
                "endDate": "12-Dec-2027",
                "successPercentage": "88%",
                "predictedDateL50": "05-Feb-2026",
                "predictedDateU50": "15-Aug-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Dec-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Sep-2027",
                "predictedDateU50": "17-Jan-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1278",
              "name": "Leukoplakia"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-May-2019",
            "endDate": "03-Apr-2028",
            "statusDate": "03-May-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "03-May-2019",
                "endDate": "13-Sep-2024",
                "successPercentage": "19%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "13-Sep-2024",
                "endDate": "13-Jun-2027",
                "successPercentage": "18%",
                "predictedDateL50": "20-Jan-2024",
                "predictedDateU50": "14-Feb-2025",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Jun-2027",
                "endDate": "25-Feb-2028",
                "successPercentage": "95%",
                "predictedDateL50": "17-Apr-2026",
                "predictedDateU50": "26-Nov-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Feb-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Dec-2027",
                "predictedDateU50": "03-Apr-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1507",
              "name": "Pancreatic ductal adenocarcinoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (FR)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Sep-2019",
            "endDate": "01-Jan-2031",
            "statusDate": "13-Sep-2019",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "7.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "13-Sep-2019",
                "endDate": "18-Sep-2024",
                "successPercentage": "63%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "18-Sep-2024",
                "endDate": "07-Apr-2027",
                "successPercentage": "10%",
                "predictedDateL50": "02-Feb-2024",
                "predictedDateU50": "18-Mar-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "07-Apr-2027",
                "endDate": "04-Jan-2030",
                "successPercentage": "14%",
                "predictedDateL50": "08-Jan-2026",
                "predictedDateU50": "05-Oct-2027",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "04-Jan-2030",
                "endDate": "22-Nov-2030",
                "successPercentage": "95%",
                "predictedDateL50": "08-Nov-2028",
                "predictedDateU50": "19-Jun-2030",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Nov-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Aug-2030",
                "predictedDateU50": "01-Jan-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-May-2021",
                "milestoneExtendedDate": "31-May-2021",
                "notes": "In March 2019, a phase I trial, CATRIPCA, in patients with non-MSI-high advanced/metastatic pancreatic ductal adenocarcinoma or colorectal cancer was expected to complete in May 2021 [<ulink linkType=\"Reference\" linkID=\"2129404\">2129404</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Other Outcome",
                "milestoneDate": "12-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, phase I trial (NCT03871959) data were presented. Of 40 patients (dose escalation and expansion) with RECIST-evaluable disease, confirmed partial response was observed in a patient with pancreatic ductal adenocarcinoma (PDAC), stable disease was observed in 4 patients and progressive disease as best response was observed in 35 patients. DLTs were not reported during dose-escalation (n = 13). The overall anti-tumor activity was low [ <ulink linkID=\"2747991\" linkType=\"Reference\">  2747991 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "FR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1507",
              "name": "Pancreatic ductal adenocarcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Jul-2019",
            "endDate": "12-Jun-2028",
            "statusDate": "31-Jul-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Jul-2019",
                "endDate": "20-Nov-2024",
                "successPercentage": "18%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "20-Nov-2024",
                "endDate": "12-Aug-2027",
                "successPercentage": "13%",
                "predictedDateL50": "12-Feb-2024",
                "predictedDateU50": "14-May-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-Aug-2027",
                "endDate": "11-May-2028",
                "successPercentage": "95%",
                "predictedDateL50": "17-Jun-2026",
                "predictedDateU50": "17-Jan-2028",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-May-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Feb-2028",
                "predictedDateU50": "12-Jun-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2021, a phase II study (NCT05132504) as neoadjuvant Folfirinox combined with pembrolizumab followed by surgery for patients with resectable pancreatic cancer, was planned to begin in January 2022 [ <ulink linkID=\"2590556\" linkType=\"Reference\">  2590556 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Nov-2022",
                "milestoneExtendedDate": "30-Nov-2022",
                "notes": "In November 2018, trial was expected to complete in November 2022 [<ulink linkType=\"Reference\" linkID=\"2089979\">2089979</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Jul-2024",
                "milestoneExtendedDate": "",
                "notes": "In November 2021, a phase II study (NCT05132504) as neoadjuvant Folfirinox combined with pembrolizumab followed by surgery for patients with resectable pancreatic cancer, was expected to complete in July 2024 [ <ulink linkID=\"2590556\" linkType=\"Reference\">  2590556 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1516",
              "name": "Biliary cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-May-2020",
            "endDate": "21-Apr-2025",
            "statusDate": "20-May-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "66%",
            "timeToRegistration": "1.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "20-May-2020",
                "endDate": "25-Jan-2024",
                "successPercentage": "69%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Jan-2024",
                "endDate": "24-Feb-2025",
                "successPercentage": "95%",
                "predictedDateL50": "04-Jul-2023",
                "predictedDateU50": "02-Jul-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "24-Feb-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-Oct-2024",
                "predictedDateU50": "21-Apr-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "24-Feb-2021",
                "milestoneExtendedDate": "",
                "notes": "In February 2021, an implied trial approval was granted for advanced and/or unresectable biliary tract cancer [<ulink linkType=\"Reference\" linkID=\"2399834\">2399834</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "26-Mar-2022",
                "milestoneExtendedDate": "",
                "notes": "In Februrary, an implied IND approval was granted for the treatment of biliary cancer[ <ulink linkID=\"2610085\" linkType=\"Reference\">  2610085 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "25-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, final data from phase III trial (NCT04003636; KEYNOTE-966) were reported [ <ulink linkID=\"2813172\" linkType=\"Reference\">  2813172 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1516",
              "name": "Biliary cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "04-Dec-2024",
            "statusDate": "24-Sep-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "61%",
            "timeToRegistration": "0.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "24-Sep-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "24-Sep-2019",
                "endDate": "25-Jan-2024",
                "successPercentage": "64%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Jan-2024",
                "endDate": "04-Nov-2024",
                "successPercentage": "95%",
                "predictedDateL50": "16-Jun-2023",
                "predictedDateU50": "12-Jun-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Nov-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Jul-2024",
                "predictedDateU50": "04-Dec-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "25-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, final data from phase III trial (NCT04003636; KEYNOTE-966) were reported [ <ulink linkID=\"2813172\" linkType=\"Reference\">  2813172 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2019, the phase III trial (KEYNOTE-966) assessing pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in patients with advanced and/or unresectable biliary tract carcinoma was expected to complete in August 2023 [<ulink linkType=\"Reference\" linkID=\"2256353\">2256353</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1516",
              "name": "Biliary cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "02-Dec-2024",
            "statusDate": "24-Sep-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "63%",
            "timeToRegistration": "0.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "18-Dec-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "18-Dec-2015",
                "endDate": "24-Sep-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "24-Sep-2019",
                "endDate": "25-Jan-2024",
                "successPercentage": "66%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Jan-2024",
                "endDate": "02-Nov-2024",
                "successPercentage": "95%",
                "predictedDateL50": "24-Aug-2023",
                "predictedDateU50": "30-May-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Nov-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "27-Jul-2024",
                "predictedDateU50": "02-Dec-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "25-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, final data from phase III trial (NCT04003636; KEYNOTE-966) were reported [ <ulink linkID=\"2813172\" linkType=\"Reference\">  2813172 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1516",
              "name": "Biliary cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "17-Feb-2014",
            "endDate": "25-Nov-2024",
            "statusDate": "24-Sep-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "76%",
            "timeToRegistration": "0.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "18-Dec-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "18-Dec-2015",
                "endDate": "24-Sep-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "24-Sep-2019",
                "endDate": "25-Jan-2024",
                "successPercentage": "80%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Jan-2024",
                "endDate": "23-Oct-2024",
                "successPercentage": "95%",
                "predictedDateL50": "06-Apr-2023",
                "predictedDateU50": "19-May-2024",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Oct-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Jul-2024",
                "predictedDateU50": "25-Nov-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "09-Oct-2019",
                "milestoneExtendedDate": "",
                "notes": "In October 2019, the US FDA granted pembrolizumab Orphan status for the treatment of biliary tract carcinoma [<ulink linkType=\"Reference\" linkID=\"2205349\">2205349</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "22-Jan-2022",
                "milestoneExtendedDate": "",
                "notes": "In January 2022, primary endpoint (overall response rate) of a phase II trial (NCT02703714) of pembrolizumab in 42 patients with biliary cancer was met. The objective response rate (ORR; primary endpoint) was 12%; median progression-free survival (PFS; secondary endpoint) was 63 days, PFS rate at month-6 was 27% and median overall survival (OS; secondary endpoint) was 93 days. A significant difference was not observed in ORR, PFS, or OS by anatomic subsite or tumor programmed cell death-ligand 1 expression; HBV/HCV+ exhibited higher ORR (30 versus 6%, p = 0.08) and longer median PFS (276 versus 63 days, p = 0.06) and OS (1033 versus 323 days, p = 0.052) [ <ulink linkID=\"2608804\" linkType=\"Reference\">  2608804 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "22-Jan-2022",
                "milestoneExtendedDate": "",
                "notes": "In January 2022, positive results of a phase II trial (NCT02703714) of pembrolizumab in 42 patients with biliary cancer were presented. The objective response rate (ORR; primary endpoint) was 12%; median progression-free survival (PFS; secondary endpoint) was 63 days, PFS rate at month-6 was 27% and median overall survival (OS; secondary endpoint) was 93 days. A significant difference was not observed in ORR, PFS, or OS by anatomic subsite or tumor programmed cell death-ligand 1 expression; HBV/HCV+ exhibited higher ORR (30 versus 6%, p = 0.08) and longer median PFS (276 versus 63 days, p = 0.06) and OS (1033 versus 323 days, p = 0.052) [ <ulink linkID=\"2608804\" linkType=\"Reference\">  2608804 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "25-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, final data from phase III trial (NCT04003636; KEYNOTE-966) were reported [ <ulink linkID=\"2813172\" linkType=\"Reference\">  2813172 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2019, the phase III trial (KEYNOTE-966) assessing pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in patients with advanced and/or unresectable biliary tract carcinoma was expected to complete in August 2023 [<ulink linkType=\"Reference\" linkID=\"2256353\">2256353</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Oct-2019",
            "endDate": "03-Jan-2027",
            "statusDate": "22-Oct-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "61%",
            "timeToRegistration": "2.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "22-Oct-2019",
                "endDate": "25-Sep-2025",
                "successPercentage": "64%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Sep-2025",
                "endDate": "03-Nov-2026",
                "successPercentage": "95%",
                "predictedDateL50": "17-Jan-2025",
                "predictedDateU50": "18-Feb-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "03-Nov-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-Jun-2026",
                "predictedDateU50": "03-Jan-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Apr-2024",
                "milestoneExtendedDate": "",
                "notes": "In May 2022, the phase III trial (NCT04865289; LEAP-001) was expected to complete in April 2024 [ <ulink linkID=\"3494284\" linkType=\"Reference\"> 3494284 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (NL)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Dec-2015",
            "endDate": "29-Nov-2021",
            "statusDate": "08-Jan-2019",
            "phaseHighestStatus": "Reg",
            "probabilityOfSuccess": null,
            "timeToRegistration": "-2.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Dec-2015",
                "endDate": "11-Jun-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "11-Jun-2018",
                "endDate": "15-Oct-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Oct-2021",
                "endDate": "29-Nov-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-Nov-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "01-Aug-2019",
                "milestoneExtendedDate": "",
                "notes": "In July 2019, a phase I/II ATAPEMBRO study for the treatment of Endometrium Cancer was to be initiated August 2019 [<ulink linkType=\"Reference\" linkID=\"2173097\">2173097</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "13-Mar-2020",
                "milestoneExtendedDate": "",
                "notes": "In March 2020, final data from the endometrial cancer cohort of the phase I/II KEYNOTE-146 (NCT02501096) study were published; at a median follow-up of 18.7 months, the objective response rate at 24 weeks was 38.0% for the overall population, and among subgroups, was 63.6% in patients with microsatellite instability (MSI)-high tumors and 36.2% in patients with microsatellite-stable tumors [<ulink linkType=\"Reference\" linkID=\"2256810\">2256810</ulink>], [<ulink linkType=\"Reference\" linkID=\"2257085\">2257085</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In October 2021, the EMA’s CHMP issued a positive opinion for the combination use of pembrolizumab plus lenvatinib for patients with advanced or recurrent endometrial carcinoma who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery or radiation, based on the KEYNOTE-775 trial; at that time, a decision from the EC was expected in 4Q21 [ <ulink linkID=\"2549726\" linkType=\"Reference\">  2549726 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "sNDA/sBLA Filing",
                "status": "Filed",
                "milestoneDate": "15-Oct-2021",
                "milestoneExtendedDate": "",
                "notes": "By October 2021, a filing had been submitted in the EU for the combination use of pembrolizumab plus lenvatinib for patients with advanced or recurrent endometrial carcinoma who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery or radiation, based on the KEYNOTE-775 trial [ <ulink linkID=\"2549726\" linkType=\"Reference\">  2549726 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "CHMP Opinion",
                "status": "Positive Opinion",
                "milestoneDate": "15-Oct-2021",
                "milestoneExtendedDate": "",
                "notes": "In October 2021, the EMA’s CHMP issued a positive opinion for the combination use of pembrolizumab plus lenvatinib for patients with advanced or recurrent endometrial carcinoma who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery or radiation, based on the KEYNOTE-775 trial; at that time, a decision from the EC was expected in 4Q21 [ <ulink linkID=\"2549726\" linkType=\"Reference\">  2549726 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "NL"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1729",
              "name": "B-cell acute lymphoblastic leukemia"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-Aug-2017",
            "endDate": "07-Jun-2028",
            "statusDate": "07-Aug-2017",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "07-Aug-2017",
                "endDate": "29-Nov-2024",
                "successPercentage": "21%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "29-Nov-2024",
                "endDate": "06-Aug-2027",
                "successPercentage": "25%",
                "predictedDateL50": "14-Feb-2024",
                "predictedDateU50": "10-Jul-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "06-Aug-2027",
                "endDate": "06-May-2028",
                "successPercentage": "95%",
                "predictedDateL50": "16-Jun-2026",
                "predictedDateU50": "07-Jan-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-May-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Feb-2028",
                "predictedDateU50": "07-Jun-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1731",
              "name": "Acute myelogenous leukemia"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Aug-2016",
            "endDate": "",
            "statusDate": "31-Aug-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Aug-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1734",
              "name": "Chronic lymphocytic leukemia"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Jul-2017",
            "endDate": "",
            "statusDate": "14-Jul-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "14-Jul-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1743",
              "name": "Lymphoplasmacytic lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe (GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "06-Sep-2019",
            "endDate": "28-Aug-2028",
            "statusDate": "06-Sep-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "6%",
            "timeToRegistration": "4.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "06-Sep-2019",
                "endDate": "14-Dec-2024",
                "successPercentage": "25%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "14-Dec-2024",
                "endDate": "29-Aug-2027",
                "successPercentage": "24%",
                "predictedDateL50": "02-Mar-2024",
                "predictedDateU50": "16-Jun-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Aug-2027",
                "endDate": "23-Jul-2028",
                "successPercentage": "95%",
                "predictedDateL50": "11-Jul-2026",
                "predictedDateU50": "06-Feb-2028",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Jul-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Apr-2028",
                "predictedDateU50": "28-Aug-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1744",
              "name": "Mantle cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Jul-2017",
            "endDate": "06-Jul-2028",
            "statusDate": "14-Jul-2017",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "14-Jul-2017",
                "endDate": "21-Jan-2025",
                "successPercentage": "23%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-Jan-2025",
                "endDate": "02-Sep-2027",
                "successPercentage": "13%",
                "predictedDateL50": "24-Feb-2024",
                "predictedDateU50": "22-Aug-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-Sep-2027",
                "endDate": "05-Jun-2028",
                "successPercentage": "94%",
                "predictedDateL50": "16-Jul-2026",
                "predictedDateU50": "23-Jan-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Jun-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Mar-2028",
                "predictedDateU50": "06-Jul-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (DE, IT)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-Dec-2019",
            "endDate": "11-Jul-2029",
            "statusDate": "07-Dec-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "5.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "07-Dec-2019",
                "endDate": "18-Dec-2025",
                "successPercentage": "25%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "18-Dec-2025",
                "endDate": "10-Jul-2028",
                "successPercentage": "12%",
                "predictedDateL50": "10-Jun-2025",
                "predictedDateU50": "11-May-2026",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Jul-2028",
                "endDate": "06-Jun-2029",
                "successPercentage": "91%",
                "predictedDateL50": "01-Jun-2027",
                "predictedDateU50": "23-Nov-2028",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-Jun-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "21-Feb-2029",
                "predictedDateU50": "11-Jul-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial termination",
                "status": "Negative Outcome",
                "milestoneDate": "06-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, data of phase Ib (NCT03340766) trial was presented. MTD was determined to be blinatumomab 56 microg/day. At that time the study was terminated due to MTD of blinatumomab in combination with pembrolizumab was lower than the MTD of blinatumomab monotherapy, with no apparent efficacy gain [ <ulink linkID=\"2692080\" linkType=\"Reference\">  2692080 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "18-Dec-2025",
                "milestoneExtendedDate": "",
                "notes": "In July 2018, it was reported that a phase I/II study was expected to complete in December 18, 2025[<ulink linkType=\"Reference\" linkID=\"2058244\">2058244</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "DE",
              " IT"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Nov-2013",
            "endDate": "07-May-2027",
            "statusDate": "07-Apr-2015",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "3.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "22-Nov-2013",
                "endDate": "07-Apr-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "07-Apr-2015",
                "endDate": "10-Dec-2023",
                "successPercentage": "30%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "02-Jul-2026",
                "successPercentage": "11%",
                "predictedDateL50": "02-Jun-2023",
                "predictedDateU50": "02-May-2024",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-Jul-2026",
                "endDate": "07-Apr-2027",
                "successPercentage": "92%",
                "predictedDateL50": "23-May-2025",
                "predictedDateU50": "15-Nov-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Apr-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Jan-2027",
                "predictedDateU50": "07-May-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "03-Jun-2019",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, the trial met its primary and secondary endpoint. </para>",
                "newMilestone": false
              },
              {
                "title": "Trial termination",
                "status": "Negative Outcome",
                "milestoneDate": "06-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, data of phase Ib trial was presented. MTD was determined to be blinatumomab 56 microg/day. At that time the study was terminated due to MTD of blinatumomab in combination with pembrolizumab was lower than the MTD of blinatumomab monotherapy, with no apparent efficacy gain [ <ulink linkID=\"2692080\" linkType=\"Reference\">  2692080 </ulink>].   </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "18-Dec-2025",
                "milestoneExtendedDate": "",
                "notes": "In July 2018, it was reported that a phase I/II study was expected to complete in December 18, 2025[<ulink linkType=\"Reference\" linkID=\"2058244\">2058244</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1750",
              "name": "Primary mediastinal large B-cell lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Dec-2015",
            "endDate": "19-Mar-2028",
            "statusDate": "02-Dec-2015",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "13%",
            "timeToRegistration": "4.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "02-Dec-2015",
                "endDate": "04-Jun-2024",
                "successPercentage": "68%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "04-Jun-2024",
                "endDate": "11-Mar-2027",
                "successPercentage": "20%",
                "predictedDateL50": "28-Oct-2023",
                "predictedDateU50": "31-Oct-2024",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "11-Mar-2027",
                "endDate": "10-Feb-2028",
                "successPercentage": "95%",
                "predictedDateL50": "08-Jan-2026",
                "predictedDateU50": "01-Sep-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Feb-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Oct-2027",
                "predictedDateU50": "19-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, positive results of a phase II trial (NCT04875195) of pembrolizumab in 66 patients were presented. IL. In all treated patients across r/r cHL/r/r PMBCL, the objective response rate was 65.0/50.0%; complete response was 33.3/33.3%; partial response was 31.7/16.7%; 12-month overalls survival rate was 91.8/62.5 months; and 12-month progression free survival rate was 37.9/33.3%. The median duration of response in PMBCL patients was 9.7 months [ <ulink linkID=\"3020967\" linkType=\"Reference\"> 3020967 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1753",
              "name": "Peripheral T-cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Jan-2016",
            "endDate": "11-Apr-2028",
            "statusDate": "22-Jan-2016",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "22-Jan-2016",
                "endDate": "07-Oct-2024",
                "successPercentage": "23%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "07-Oct-2024",
                "endDate": "08-Jun-2027",
                "successPercentage": "21%",
                "predictedDateL50": "24-Jan-2024",
                "predictedDateU50": "13-May-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Jun-2027",
                "endDate": "11-Mar-2028",
                "successPercentage": "95%",
                "predictedDateL50": "20-Apr-2026",
                "predictedDateU50": "09-Nov-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Mar-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Dec-2027",
                "predictedDateU50": "11-Apr-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1754",
              "name": "Cutaneous T-cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Nov-2017",
            "endDate": "26-May-2027",
            "statusDate": "14-Nov-2017",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "14-Nov-2017",
                "endDate": "10-Dec-2023",
                "successPercentage": "30%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "21-Jul-2026",
                "successPercentage": "18%",
                "predictedDateL50": "02-Mar-2023",
                "predictedDateU50": "12-Jul-2024",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Jul-2026",
                "endDate": "26-Apr-2027",
                "successPercentage": "94%",
                "predictedDateL50": "03-Jun-2025",
                "predictedDateU50": "11-Dec-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Apr-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "20-Jan-2027",
                "predictedDateU50": "26-May-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "07-Dec-2019",
                "milestoneExtendedDate": "",
                "notes": "In December 2019, clinical data from trial (NCT03278782) were presented at 61st ASH Annual Meeting and Exposition in Orlando, FL [<ulink linkType=\"Reference\" linkID=\"2225892\">2225892</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1756",
              "name": "Sezary syndrome"
            },
            "country": {
              "id": "EU",
              "name": "Europe (GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Jan-2019",
            "endDate": "29-Oct-2028",
            "statusDate": "15-Jan-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "15-Jan-2019",
                "endDate": "10-Feb-2025",
                "successPercentage": "25%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Feb-2025",
                "endDate": "01-Nov-2027",
                "successPercentage": "18%",
                "predictedDateL50": "18-Mar-2024",
                "predictedDateU50": "10-Aug-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-Nov-2027",
                "endDate": "23-Sep-2028",
                "successPercentage": "95%",
                "predictedDateL50": "10-Sep-2026",
                "predictedDateU50": "10-Apr-2028",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Sep-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Jun-2028",
                "predictedDateU50": "29-Oct-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2024",
                "milestoneExtendedDate": "31-Jul-2024",
                "notes": "In January 2019, a phase II was expected to complete in July 2024 [<ulink linkType=\"Reference\" linkID=\"2116222\">2116222</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1764",
              "name": "Basal cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "23-Feb-2016",
            "endDate": "",
            "statusDate": "23-Feb-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "23-Feb-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1765",
              "name": "Cholangiocarcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Jun-2021",
            "endDate": "28-Nov-2025",
            "statusDate": "11-Jun-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "49%",
            "timeToRegistration": "1.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "11-Jun-2021",
                "endDate": "31-Aug-2024",
                "successPercentage": "52%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Aug-2024",
                "endDate": "01-Oct-2025",
                "successPercentage": "95%",
                "predictedDateL50": "15-Feb-2024",
                "predictedDateU50": "14-Jan-2025",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Oct-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-May-2025",
                "predictedDateU50": "28-Nov-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1766",
              "name": "Renal cell carcinoma"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Dec-2014",
            "endDate": "",
            "statusDate": "03-Dec-2014",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "03-Dec-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1766",
              "name": "Renal cell carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2016",
            "endDate": "27-Jan-2022",
            "statusDate": "09-Jun-2017",
            "phaseHighestStatus": "Reg",
            "probabilityOfSuccess": null,
            "timeToRegistration": "-1.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Sep-2016",
                "endDate": "09-Jun-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "09-Jun-2017",
                "endDate": "27-Jan-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Jan-2022",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "08-Apr-2021",
                "milestoneExtendedDate": "",
                "notes": "In April 2021, the phase III KEYNOTE-564 trial evaluating pembrolizumab versus placebo as an aduvant treatment of renal cell carcinoma following surgery, met its primary endpoint of superior disease-free survival versus placebo, based on an interim analysis by an independent DMC [2432834].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "08-Apr-2021",
                "milestoneExtendedDate": "",
                "notes": "In April 2021, the phase III KEYNOTE-564 trial evaluating pembrolizumab versus placebo as an aduvant treatment of renal cell carcinoma following surgery, met its primary endpoint of superior disease-free survival versus placebo, based on an interim analysis by an independent DMC [2432834].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Planned",
                "milestoneDate": "08-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, data from the phase III KEYNOTE-426 trial in combination with axitinib as a first-line treatment for patients with advanced or metastatic renal cell carcinoma were expected in June 2021 [2448754].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "08-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, data from the phase III KEYNOTE-564 study of pembrolizumab as monotherapy in the adjuvant treatment of patients (expected n = 950) with renal cell carcinoma post-nephrectomy were expected in June 2021 [2448754].</para>",
                "newMilestone": false
              },
              {
                "title": "CHMP Opinion",
                "status": "Positive Opinion",
                "milestoneDate": "17-Dec-2021",
                "milestoneExtendedDate": "",
                "notes": "By December 2021, a filing had been submitted in the EU for the monotherapy use of pembrolizumab in adults with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions, based on data from the KEYNOTE-564 study; at that time, the CHMP issued a positive opinion and a decision from the EC was expected in 1Q22 [ <ulink linkID=\"2585801\" linkType=\"Reference\">  2585801 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Mar-2022",
                "notes": "By December 2021, a filing had been submitted in the EU for the monotherapy use of pembrolizumab in adults with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions, based on data from the KEYNOTE-564 study; at that time, the CHMP issued a positive opinion and a decision from the EC was expected in 1Q22 [ <ulink linkID=\"2585801\" linkType=\"Reference\">  2585801 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Apr-2017",
            "endDate": "11-Oct-2028",
            "statusDate": "27-Apr-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "27-Apr-2017",
                "endDate": "12-Jul-2027",
                "successPercentage": "5%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "10.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-Jul-2027",
                "endDate": "14-Aug-2028",
                "successPercentage": "95%",
                "predictedDateL50": "24-Dec-2026",
                "predictedDateU50": "02-Oct-2027",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Aug-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Apr-2028",
                "predictedDateU50": "11-Oct-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "30-Apr-2019",
                "milestoneExtendedDate": "",
                "notes": "By April 2019, Merck received an implied clinical trial approval for hepatocellular carcinoma in China [<ulink linkType=\"Reference\" linkID=\"2142223\">2142223</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "03-Feb-2020",
                "milestoneExtendedDate": "",
                "notes": "In February 2020, an IND was filed in China [<ulink linkType=\"Reference\" linkID=\"2241197\">2241197</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "15-Apr-2020",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, an implied clinical trial approval of the drug was granted for hepatocellular carcinoma in China [<ulink linkType=\"Reference\" linkID=\"2260929\">2260929</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "24-Aug-2021",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, an implied trial approval was granted for hepatocellular carcinoma in China [ <ulink linkID=\"2502642\" linkType=\"Reference\">  2502642 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "23-Jul-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2018, the phase III LEAP-002 trial evaluating lenvatinib + pembrolizumab versus lenvatinib as first-line therapy in adult patients with advanced hepatocellular carcinoma was expected to complete in July 2022 [<ulink linkType=\"Reference\" linkID=\"2178543\">2178543</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "03-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, data from  phase III trial (NCT03713593; LEAP-002) of drug in combination with lenvatinib were reported  [ <ulink linkID=\"2713325\" linkType=\"Reference\">  2713325 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "03-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, a phase III trial (NCT03713593; LEAP-002) of drug in combination with lenvatinib did not meet primary endpoints [ <ulink linkID=\"2713325\" linkType=\"Reference\">  2713325 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-May-2019",
            "endDate": "30-Jul-2027",
            "statusDate": "31-Dec-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "28-May-2019",
                "endDate": "15-Sep-2026",
                "successPercentage": "5%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Sep-2026",
                "endDate": "30-Jun-2027",
                "successPercentage": "95%",
                "predictedDateL50": "04-Mar-2026",
                "predictedDateU50": "05-Dec-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "20-Mar-2027",
                "predictedDateU50": "30-Jul-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "23-Jul-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2018, the phase III LEAP-002 trial evaluating lenvatinib + pembrolizumab versus lenvatinib as first-line therapy in adult patients with advanced hepatocellular carcinoma was expected to complete in July 2022 [<ulink linkType=\"Reference\" linkID=\"2178543\">2178543</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "03-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, data from phase III trial (NCT03713593; LEAP-002) of drug in combination with lenvatinib were reported [ <ulink linkID=\"2713325\" linkType=\"Reference\">  2713325 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "03-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, a phase III trial (NCT03713593; LEAP-002) of drug in combination with lenvatinib did not meet primary endpoints [ <ulink linkID=\"2713325\" linkType=\"Reference\">  2713325 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Apr-2017",
            "endDate": "12-Mar-2028",
            "statusDate": "31-May-2016",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "27-Apr-2017",
                "endDate": "03-May-2027",
                "successPercentage": "5%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "10.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-May-2027",
                "endDate": "11-Feb-2028",
                "successPercentage": "95%",
                "predictedDateL50": "18-Nov-2026",
                "predictedDateU50": "20-Jul-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Feb-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-Nov-2027",
                "predictedDateU50": "12-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "23-Jul-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2018, the phase III LEAP-002 trial evaluating lenvatinib + pembrolizumab versus lenvatinib as first-line therapy in adult patients with advanced hepatocellular carcinoma was expected to complete in July 2022 [<ulink linkType=\"Reference\" linkID=\"2178543\">2178543</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "03-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, a phase III trial (NCT03713593; LEAP-002) of drug in combination with lenvatinib did not meet primary endpoints [ <ulink linkID=\"2713325\" linkType=\"Reference\">  2713325 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "03-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, data from phase III trial (NCT03713593; LEAP-002) of drug in combination with lenvatinib were reported [ <ulink linkID=\"2713325\" linkType=\"Reference\">  2713325 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-May-2016",
            "endDate": "30-Jan-2029",
            "statusDate": "31-May-2016",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "5.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-May-2016",
                "endDate": "31-May-2016",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "31-May-2016",
                "endDate": "27-Dec-2027",
                "successPercentage": "5%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "11.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Dec-2027",
                "endDate": "21-Dec-2028",
                "successPercentage": "95%",
                "predictedDateL50": "03-Jun-2027",
                "predictedDateU50": "29-Mar-2028",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-Dec-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Aug-2028",
                "predictedDateU50": "30-Jan-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "19-Feb-2019",
                "milestoneExtendedDate": "",
                "notes": "In February 2019, results were reported from the phase III trial KEYNOTE-240 study in second-line HCC, showing that the co-primary endpoints of OS and PFS were not met [<ulink linkType=\"Reference\" linkID=\"2121085\">2121085</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Dec-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2019, trial was estimated to complete in December 2020 [<ulink linkType=\"Reference\" linkID=\"2199017\">2199017</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In November 2021, a phase II (NCT05101629)  trial was  planned to begin in  December 2021 [2589653].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "23-Jul-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2018, the phase III LEAP-002 trial evaluating lenvatinib + pembrolizumab versus lenvatinib as first-line therapy in adult patients with advanced hepatocellular was expected to complete in July 2022 [<ulink linkType=\"Reference\" linkID=\"2178543\">2178543</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "03-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, data from phase III trial (NCT03713593; LEAP-002) of drug in combination with lenvatinib were reported [ <ulink linkID=\"2713325\" linkType=\"Reference\">  2713325 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "03-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, a phase III trial (NCT03713593; LEAP-002) of drug in combination with lenvatinib did not meet primary endpoints [ <ulink linkID=\"2713325\" linkType=\"Reference\">  2713325 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In November 2021, a phase II (NCT05101629)  trial was expected to complete in December 2024 [ <ulink linkID=\"2589653\" linkType=\"Reference\">  2589653 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1768",
              "name": "Nasopharyngeal carcinoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "",
            "statusDate": "31-Aug-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "25-Aug-2016",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "25-Aug-2016",
                "endDate": "31-Aug-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "31-Aug-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1768",
              "name": "Nasopharyngeal carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "17-Feb-2014",
            "endDate": "03-Nov-2025",
            "statusDate": "31-Aug-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "45%",
            "timeToRegistration": "1.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "28-Apr-2016",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "28-Apr-2016",
                "endDate": "31-Aug-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "31-Aug-2017",
                "endDate": "31-Dec-2024",
                "successPercentage": "47%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Dec-2024",
                "endDate": "03-Oct-2025",
                "successPercentage": "95%",
                "predictedDateL50": "06-Mar-2024",
                "predictedDateU50": "02-May-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "03-Oct-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Jun-2025",
                "predictedDateU50": "03-Nov-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "11-Oct-2016",
                "milestoneExtendedDate": "",
                "notes": null,
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In February 2019, data from a phase III trial (KEYNOTE-122) in second-line nasopharyngeal carcinoma were expected in 2020 [<ulink linkType=\"Reference\" linkID=\"2116422\">2116422</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Apr-2023",
            "endDate": "04-Jan-2027",
            "statusDate": "03-Apr-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "56%",
            "timeToRegistration": "2.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "03-Apr-2023",
                "endDate": "07-Oct-2025",
                "successPercentage": "59%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Oct-2025",
                "endDate": "07-Nov-2026",
                "successPercentage": "95%",
                "predictedDateL50": "24-Sep-2024",
                "predictedDateU50": "16-Feb-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Nov-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Jul-2026",
                "predictedDateU50": "04-Jan-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-May-2013",
            "endDate": "11-Aug-2025",
            "statusDate": "10-Jun-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "58%",
            "timeToRegistration": "1.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "07-May-2013",
                "endDate": "22-Oct-2014",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "22-Oct-2014",
                "endDate": "02-Oct-2024",
                "successPercentage": "61%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "9.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-Oct-2024",
                "endDate": "12-Jul-2025",
                "successPercentage": "95%",
                "predictedDateL50": "21-Jan-2024",
                "predictedDateU50": "04-Jan-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Jul-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Apr-2025",
                "predictedDateU50": "11-Aug-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Oct-2014",
            "endDate": "31-May-2025",
            "statusDate": "10-Jun-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "58%",
            "timeToRegistration": "1.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "22-Oct-2014",
                "endDate": "24-Jul-2024",
                "successPercentage": "61%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "9.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "24-Jul-2024",
                "endDate": "01-May-2025",
                "successPercentage": "95%",
                "predictedDateL50": "15-Jan-2024",
                "predictedDateU50": "24-Oct-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-May-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Jan-2025",
                "predictedDateU50": "31-May-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US, US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-May-2013",
            "endDate": "31-Aug-2021",
            "statusDate": "31-Aug-2021",
            "phaseHighestStatus": "Reg",
            "probabilityOfSuccess": null,
            "timeToRegistration": "-2.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "07-May-2013",
                "endDate": "10-Feb-2016",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "10-Feb-2016",
                "endDate": "30-Sep-2016",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "30-Sep-2016",
                "endDate": "31-Aug-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.11",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "31-Aug-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US",
              " US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Feb-2016",
            "endDate": "19-Dec-2025",
            "statusDate": "10-Jun-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "56%",
            "timeToRegistration": "1.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "10-Feb-2016",
                "endDate": "10-Jun-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Jun-2017",
                "endDate": "18-Nov-2024",
                "successPercentage": "59%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "18-Nov-2024",
                "endDate": "10-Nov-2025",
                "successPercentage": "95%",
                "predictedDateL50": "06-Feb-2024",
                "predictedDateU50": "24-Feb-2025",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Nov-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-Jul-2025",
                "predictedDateU50": "19-Dec-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "26-Jul-2022",
                "milestoneExtendedDate": "",
                "notes": "In July 2022, positive topline data from phase I/II trial (NCT03288545; KEYNOTE-869) were reported [ <ulink linkID=\"2708659\" linkType=\"Reference\">  2708659 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In May 2019, the phase III trial in locally advanced or metastatic urothelial carcinoma was to complete in December 2022 [<ulink linkType=\"Reference\" linkID=\"2137655\">2137655</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1772",
              "name": "Osteosarcoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe (IT, NO)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-May-2017",
            "endDate": "13-Oct-2028",
            "statusDate": "30-May-2017",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-May-2017",
                "endDate": "27-Jan-2025",
                "successPercentage": "25%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "27-Jan-2025",
                "endDate": "18-Oct-2027",
                "successPercentage": "13%",
                "predictedDateL50": "05-Feb-2024",
                "predictedDateU50": "29-Jul-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "18-Oct-2027",
                "endDate": "04-Sep-2028",
                "successPercentage": "95%",
                "predictedDateL50": "27-Aug-2026",
                "predictedDateU50": "27-Mar-2028",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Sep-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-May-2028",
                "predictedDateU50": "13-Oct-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Jun-2024",
                "milestoneExtendedDate": "",
                "notes": "In January 2022, Institut Bergonie sponsored in collaboration with MSD France and Ipsen planned for a phase II study in combination with cabozantinib in advanced sarcomas patients including undiffenrentiated pleomorphic sarcoma, soft tissue sarcoma, osteosarcoma and ewing sarcoma was expected to complete in June 2024  [2613869].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "IT",
              " NO"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1791",
              "name": "Penis tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Oct-2016",
            "endDate": "05-Jun-2028",
            "statusDate": "31-Oct-2016",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Oct-2016",
                "endDate": "01-Dec-2024",
                "successPercentage": "24%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Dec-2024",
                "endDate": "31-Aug-2027",
                "successPercentage": "18%",
                "predictedDateL50": "29-Feb-2024",
                "predictedDateU50": "19-Apr-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Aug-2027",
                "endDate": "02-May-2028",
                "successPercentage": "95%",
                "predictedDateL50": "05-Jul-2026",
                "predictedDateU50": "13-Feb-2028",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-May-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Feb-2028",
                "predictedDateU50": "05-Jun-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "2049",
              "name": "Adrenal gland tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Feb-2016",
            "endDate": "",
            "statusDate": "10-Feb-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "10-Feb-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "2054",
              "name": "Hematological neoplasm"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Nov-2013",
            "endDate": "",
            "statusDate": "30-Nov-2013",
            "phaseHighestStatus": "Repositioned",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "30-Nov-2013",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "2170",
              "name": "Skin cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "26-Oct-2017",
            "endDate": "",
            "statusDate": "26-Oct-2017",
            "phaseHighestStatus": "Repositioned",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "-1.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "26-Oct-2017",
                "endDate": "12-Sep-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "12-Sep-2018",
                "endDate": "24-Jun-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "24-Jun-2022",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "2193",
              "name": "Anal tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "",
            "statusDate": "30-Sep-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "18-Dec-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "18-Dec-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "2243",
              "name": "Fallopian tube cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "26-Jun-2026",
            "statusDate": "18-Dec-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "29%",
            "timeToRegistration": "2.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "18-Dec-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "18-Dec-2018",
                "endDate": "08-Aug-2025",
                "successPercentage": "31%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Aug-2025",
                "endDate": "27-May-2026",
                "successPercentage": "95%",
                "predictedDateL50": "01-Apr-2025",
                "predictedDateU50": "04-Dec-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-May-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Feb-2026",
                "predictedDateU50": "26-Jun-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "08-Aug-2025",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, the randomized, phase III trial (NCT03740165; MK-7339-001/KEYLYNK-001/ENGOT-ov43) assessing first-line treatment using carboplatin/paclitaxel plus pembrolizumab and maintenance olaparib in women (expected n = 1086) with BRCA non-mutated advanced, epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer was expected to complete in August 2025 [<ulink linkType=\"Reference\" linkID=\"2169047\">2169047</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "2243",
              "name": "Fallopian tube cancer"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Apr-2022",
            "endDate": "15-Aug-2028",
            "statusDate": "28-Apr-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "28-Apr-2022",
                "endDate": "20-Nov-2024",
                "successPercentage": "41%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "20-Nov-2024",
                "endDate": "12-Aug-2027",
                "successPercentage": "12%",
                "predictedDateL50": "15-Mar-2024",
                "predictedDateU50": "21-Mar-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-Aug-2027",
                "endDate": "10-Jul-2028",
                "successPercentage": "95%",
                "predictedDateL50": "17-Jun-2026",
                "predictedDateU50": "17-Jan-2028",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Jul-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Mar-2028",
                "predictedDateU50": "15-Aug-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "2243",
              "name": "Fallopian tube cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "28-Mar-2028",
            "statusDate": "30-Sep-2016",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "30-Sep-2016",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "30-Sep-2016",
                "endDate": "04-Sep-2024",
                "successPercentage": "43%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "04-Sep-2024",
                "endDate": "12-May-2027",
                "successPercentage": "9%",
                "predictedDateL50": "19-Feb-2024",
                "predictedDateU50": "12-Jan-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-May-2027",
                "endDate": "27-Feb-2028",
                "successPercentage": "95%",
                "predictedDateL50": "24-Mar-2026",
                "predictedDateU50": "18-Oct-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Feb-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-Nov-2027",
                "predictedDateU50": "28-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "20-Nov-2018",
                "milestoneExtendedDate": "",
                "notes": "In November 2018, a phase I/II trial was expected to initiate on November 20, 2018 [<ulink linkType=\"Reference\" linkID=\"2094214\">2094214</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In November 2018, a phase I/II trial was expected to complete on November 20, 2023 [<ulink linkType=\"Reference\" linkID=\"2094214\">2094214</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "2243",
              "name": "Fallopian tube cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "29-Aug-2026",
            "statusDate": "18-Dec-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "20%",
            "timeToRegistration": "2.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "25-Feb-2016",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "25-Feb-2016",
                "endDate": "18-Dec-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "18-Dec-2018",
                "endDate": "08-Aug-2025",
                "successPercentage": "21%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Aug-2025",
                "endDate": "19-Jul-2026",
                "successPercentage": "95%",
                "predictedDateL50": "30-Mar-2025",
                "predictedDateU50": "01-Dec-2025",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Jul-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Mar-2026",
                "predictedDateU50": "29-Aug-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "08-Aug-2025",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, the randomized, phase III trial (NCT03740165; MK-7339-001/KEYLYNK-001/ENGOT-ov43) assessing first-line treatment using carboplatin/paclitaxel plus pembrolizumab and maintenance olaparib in women (expected n = 1086) with BRCA non-mutated advanced, epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer was expected to complete in August 2025 [<ulink linkType=\"Reference\" linkID=\"2169047\">2169047</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "2380",
              "name": "Bladder cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Feb-2016",
            "endDate": "11-Jan-2026",
            "statusDate": "10-Feb-2016",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "39%",
            "timeToRegistration": "2.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "10-Feb-2016",
                "endDate": "24-Jul-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "24-Jul-2019",
                "endDate": "26-Feb-2025",
                "successPercentage": "41%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Feb-2025",
                "endDate": "12-Dec-2025",
                "successPercentage": "95%",
                "predictedDateL50": "23-Jul-2024",
                "predictedDateU50": "01-Jun-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Dec-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "31-Aug-2025",
                "predictedDateU50": "11-Jan-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-Mar-2019",
                "milestoneExtendedDate": "",
                "notes": "In March 2019, updated interim phase II data showed complete response in 40.2% of 102 non-muscle invasive bladder cancer patients [<ulink linkType=\"Reference\" linkID=\"2128594\">2128594</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "2380",
              "name": "Bladder cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Feb-2016",
            "endDate": "13-Apr-2026",
            "statusDate": "10-Feb-2016",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "37%",
            "timeToRegistration": "2.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "10-Feb-2016",
                "endDate": "24-Jul-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "24-Jul-2019",
                "endDate": "06-Apr-2025",
                "successPercentage": "39%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "06-Apr-2025",
                "endDate": "06-Mar-2026",
                "successPercentage": "95%",
                "predictedDateL50": "25-Jul-2024",
                "predictedDateU50": "08-Jul-2025",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-Mar-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Nov-2025",
                "predictedDateU50": "13-Apr-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-Mar-2019",
                "milestoneExtendedDate": "",
                "notes": "In March 2019, updated interim phase II data showed complete response in 40.2% of 102 non-muscle invasive bladder cancer patients [<ulink linkType=\"Reference\" linkID=\"2128594\">2128594</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "2399",
              "name": "Adenocarcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "",
            "statusDate": "23-May-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "11-May-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "11-May-2015",
                "endDate": "23-May-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-May-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "2436",
              "name": "Myelofibrosis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Jun-2017",
            "endDate": "16-Oct-2028",
            "statusDate": "14-Jun-2017",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "13%",
            "timeToRegistration": "4.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "14-Jun-2017",
                "endDate": "28-Mar-2025",
                "successPercentage": "37%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "28-Mar-2025",
                "endDate": "27-Nov-2027",
                "successPercentage": "37%",
                "predictedDateL50": "26-Feb-2024",
                "predictedDateU50": "28-Sep-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Nov-2027",
                "endDate": "15-Sep-2028",
                "successPercentage": "95%",
                "predictedDateL50": "09-Oct-2026",
                "predictedDateU50": "29-Apr-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-Sep-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-May-2028",
                "predictedDateU50": "16-Oct-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "2454",
              "name": "Glioblastoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Apr-2015",
            "endDate": "",
            "statusDate": "29-Apr-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "29-Apr-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "2614",
              "name": "Carcinosarcoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-Dec-2021",
            "endDate": "31-Oct-2026",
            "statusDate": "07-Dec-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "57%",
            "timeToRegistration": "2.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "07-Dec-2021",
                "endDate": "03-Feb-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "03-Feb-2022",
                "endDate": "04-Jan-2026",
                "successPercentage": "60%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "04-Jan-2026",
                "endDate": "26-Sep-2026",
                "successPercentage": "95%",
                "predictedDateL50": "10-Apr-2025",
                "predictedDateU50": "29-Jun-2026",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Sep-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Jun-2026",
                "predictedDateU50": "31-Oct-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "23-Dec-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2022, a phase II trial (NCT05147558) in patients with advanced uterine carcinosarcoma was expected to complete in December 2023 [ <ulink linkID=\"2595611\" linkType=\"Reference\">  2595611 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "2802",
              "name": "Meningioma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-Nov-2017",
            "endDate": "15-Jul-2028",
            "statusDate": "07-Nov-2017",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "07-Nov-2017",
                "endDate": "15-Dec-2024",
                "successPercentage": "23%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "15-Dec-2024",
                "endDate": "14-Sep-2027",
                "successPercentage": "13%",
                "predictedDateL50": "07-Mar-2024",
                "predictedDateU50": "18-Jul-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "14-Sep-2027",
                "endDate": "12-Jun-2028",
                "successPercentage": "95%",
                "predictedDateL50": "19-Jul-2026",
                "predictedDateU50": "27-Feb-2028",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Jun-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Mar-2028",
                "predictedDateU50": "15-Jul-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "2938",
              "name": "Thymus neoplasm"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Aug-2015",
            "endDate": "02-Dec-2028",
            "statusDate": "14-Aug-2015",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "10%",
            "timeToRegistration": "4.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "14-Aug-2015",
                "endDate": "17-Apr-2025",
                "successPercentage": "37%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "9.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "17-Apr-2025",
                "endDate": "15-Jan-2028",
                "successPercentage": "28%",
                "predictedDateL50": "26-Mar-2024",
                "predictedDateU50": "28-Dec-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Jan-2028",
                "endDate": "01-Nov-2028",
                "successPercentage": "95%",
                "predictedDateL50": "19-Nov-2026",
                "predictedDateU50": "29-Jun-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Nov-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Jul-2028",
                "predictedDateU50": "02-Dec-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "2938",
              "name": "Thymus neoplasm"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Sep-2021",
            "endDate": "17-Aug-2028",
            "statusDate": "21-Sep-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "11%",
            "timeToRegistration": "4.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "21-Sep-2021",
                "endDate": "07-Nov-2024",
                "successPercentage": "40%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "07-Nov-2024",
                "endDate": "07-Aug-2027",
                "successPercentage": "30%",
                "predictedDateL50": "13-Mar-2024",
                "predictedDateU50": "24-Apr-2025",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Aug-2027",
                "endDate": "08-Jul-2028",
                "successPercentage": "95%",
                "predictedDateL50": "11-Jun-2026",
                "predictedDateU50": "20-Jan-2028",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-Jul-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Mar-2028",
                "predictedDateU50": "17-Aug-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Oct-2023",
                "milestoneExtendedDate": "31-Oct-2023",
                "notes": "In September 2021, a phase II trial (NCT04710628) of the combination of pembrolizumab and lenvatinib in pre-treated patients with relapsed/recurrent thymic carcinoma who have progressed after at least one line of platinum-based chemotherapy for advanced disease was estimated to be completed in October 2023 [ <ulink linkID=\"2787079\" linkType=\"Reference\">  2787079 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "2939",
              "name": "Thymoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "06-Dec-2017",
            "endDate": "",
            "statusDate": "06-Dec-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "06-Dec-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3083",
              "name": "Peritoneal tumor"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "22-Jun-2026",
            "statusDate": "18-Dec-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "33%",
            "timeToRegistration": "2.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "18-Dec-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "18-Dec-2018",
                "endDate": "08-Aug-2025",
                "successPercentage": "35%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Aug-2025",
                "endDate": "23-May-2026",
                "successPercentage": "95%",
                "predictedDateL50": "01-Apr-2025",
                "predictedDateU50": "04-Dec-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-May-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Feb-2026",
                "predictedDateU50": "22-Jun-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "08-Aug-2025",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, the randomized, phase III trial (NCT03740165; MK-7339-001/KEYLYNK-001/ENGOT-ov43) assessing first-line treatment using carboplatin/paclitaxel plus pembrolizumab and maintenance olaparib in women (expected n = 1086) with BRCA non-mutated advanced, epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer was expected to complete in August 2025 [<ulink linkType=\"Reference\" linkID=\"2169047\">2169047</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3083",
              "name": "Peritoneal tumor"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Apr-2022",
            "endDate": "20-Aug-2028",
            "statusDate": "28-Apr-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "28-Apr-2022",
                "endDate": "29-Nov-2024",
                "successPercentage": "33%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "29-Nov-2024",
                "endDate": "21-Aug-2027",
                "successPercentage": "14%",
                "predictedDateL50": "18-Mar-2024",
                "predictedDateU50": "02-Apr-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Aug-2027",
                "endDate": "15-Jul-2028",
                "successPercentage": "95%",
                "predictedDateL50": "26-Jun-2026",
                "predictedDateU50": "26-Jan-2028",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-Jul-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Apr-2028",
                "predictedDateU50": "20-Aug-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3083",
              "name": "Peritoneal tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "01-Apr-2028",
            "statusDate": "30-Sep-2016",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "30-Sep-2016",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "30-Sep-2016",
                "endDate": "14-Sep-2024",
                "successPercentage": "35%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "14-Sep-2024",
                "endDate": "22-May-2027",
                "successPercentage": "11%",
                "predictedDateL50": "22-Feb-2024",
                "predictedDateU50": "25-Jan-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-May-2027",
                "endDate": "02-Mar-2028",
                "successPercentage": "95%",
                "predictedDateL50": "03-Apr-2026",
                "predictedDateU50": "28-Oct-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Mar-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Nov-2027",
                "predictedDateU50": "01-Apr-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "20-Nov-2018",
                "milestoneExtendedDate": "",
                "notes": "In November 2018, a phase I/II trial was expected to initiate on November 20, 2018 [<ulink linkType=\"Reference\" linkID=\"2094214\">2094214</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In November 2018, a phase I/II trial was expected to complete on November 20, 2023 [<ulink linkType=\"Reference\" linkID=\"2094214\">2094214</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3083",
              "name": "Peritoneal tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "20-Aug-2026",
            "statusDate": "18-Dec-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "24%",
            "timeToRegistration": "2.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "25-Feb-2016",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "25-Feb-2016",
                "endDate": "18-Dec-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "18-Dec-2018",
                "endDate": "08-Aug-2025",
                "successPercentage": "25%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Aug-2025",
                "endDate": "11-Jul-2026",
                "successPercentage": "94%",
                "predictedDateL50": "30-Mar-2025",
                "predictedDateU50": "01-Dec-2025",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Jul-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Mar-2026",
                "predictedDateU50": "20-Aug-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "08-Aug-2025",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, the randomized, phase III trial (NCT03740165; MK-7339-001/KEYLYNK-001/ENGOT-ov43) assessing first-line treatment using carboplatin/paclitaxel plus pembrolizumab and maintenance olaparib in women (expected n = 1086) with BRCA non-mutated advanced, epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer was expected to complete in August 2025 [<ulink linkType=\"Reference\" linkID=\"2169047\">2169047</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3153",
              "name": "Adenoid tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Apr-2017",
            "endDate": "07-Oct-2028",
            "statusDate": "25-Apr-2017",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "25-Apr-2017",
                "endDate": "07-Mar-2025",
                "successPercentage": "23%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "07-Mar-2025",
                "endDate": "05-Dec-2027",
                "successPercentage": "25%",
                "predictedDateL50": "23-Feb-2024",
                "predictedDateU50": "27-Jul-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Dec-2027",
                "endDate": "06-Sep-2028",
                "successPercentage": "95%",
                "predictedDateL50": "09-Oct-2026",
                "predictedDateU50": "19-May-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-Sep-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "03-Jun-2028",
                "predictedDateU50": "07-Oct-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3246",
              "name": "Hormone refractory prostate cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "23-Jun-2020",
            "endDate": "11-Apr-2027",
            "statusDate": "23-Jun-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "3.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "23-Jun-2020",
                "endDate": "22-Feb-2026",
                "successPercentage": "5%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Feb-2026",
                "endDate": "22-Feb-2027",
                "successPercentage": "95%",
                "predictedDateL50": "30-Aug-2025",
                "predictedDateU50": "22-Jun-2026",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Feb-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Oct-2026",
                "predictedDateU50": "11-Apr-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "03-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, data from a phase III trial (NCT03834506) of drug in combination with chemotherapy compared to chemotherapy alone were reported from metastatic castration resistant prostate cancer patients  [ <ulink linkID=\"2713326\" linkType=\"Reference\">  2713326 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "03-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, a phase III trial (NCT03834506) of drug in combination with chemotherapy compared to chemotherapy did not meet primary endpoints [ <ulink linkID=\"2713326\" linkType=\"Reference\">  2713326  </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3246",
              "name": "Hormone refractory prostate cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Jul-2016",
            "endDate": "06-Jun-2027",
            "statusDate": "08-Aug-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Jul-2016",
                "endDate": "08-Aug-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "08-Aug-2019",
                "endDate": "13-Aug-2026",
                "successPercentage": "5%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Aug-2026",
                "endDate": "30-Apr-2027",
                "successPercentage": "95%",
                "predictedDateL50": "08-Jan-2026",
                "predictedDateU50": "27-Nov-2026",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Apr-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Feb-2027",
                "predictedDateU50": "06-Jun-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "03-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, a phase III trial (NCT03834506) of drug in combination with chemotherapy compared to chemotherapy did not meet primary endpoints [ <ulink linkID=\"2713326\" linkType=\"Reference\">  2713326  </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "03-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, data from a phase III trial (NCT03834506) of drug in combination with chemotherapy compared to chemotherapy alone were reported from metastatic castration resistant prostate cancer patients  [ <ulink linkID=\"2713326\" linkType=\"Reference\">  2713326 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3246",
              "name": "Hormone refractory prostate cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Jul-2016",
            "endDate": "17-May-2027",
            "statusDate": "09-May-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Jul-2016",
                "endDate": "09-May-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "09-May-2019",
                "endDate": "26-Jul-2026",
                "successPercentage": "5%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Jul-2026",
                "endDate": "09-Apr-2027",
                "successPercentage": "95%",
                "predictedDateL50": "09-Feb-2026",
                "predictedDateU50": "26-Sep-2026",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Apr-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-Jan-2027",
                "predictedDateU50": "17-May-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "03-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, data from a phase III trial (NCT03834506) of drug in combination with chemotherapy compared to chemotherapy alone were reported from metastatic castration resistant prostate cancer patients  [ <ulink linkID=\"2713326\" linkType=\"Reference\">  2713326 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "03-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, a phase III trial (NCT03834506) of drug in combination with chemotherapy compared to chemotherapy did not meet primary endpoints [ <ulink linkID=\"2713326\" linkType=\"Reference\">  2713326  </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3246",
              "name": "Hormone refractory prostate cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "08-Apr-2015",
            "endDate": "04-Aug-2027",
            "statusDate": "02-May-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "08-Apr-2015",
                "endDate": "02-May-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-May-2019",
                "endDate": "15-Oct-2026",
                "successPercentage": "5%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Oct-2026",
                "endDate": "29-Jun-2027",
                "successPercentage": "95%",
                "predictedDateL50": "04-Apr-2026",
                "predictedDateU50": "31-Jan-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "03-Apr-2027",
                "predictedDateU50": "04-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "14-Feb-2019",
                "milestoneExtendedDate": "",
                "notes": "In February 2019, interim data were presented from the phase II umbrella trial (KEYNOTE-365) at the 2019 ASCO Genitourinary Cancers Symposium in San Francisco, CA, showing antitumor activity in combination with olaparib (cohort A), docetaxel and prednisone (cohort B) and enzalutamide (cohort C), and a safety profile consistent with each therapy alone. Phase III trials were under initiation based on these findings [<ulink linkType=\"Reference\" linkID=\"2119918\">2119918</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "30-Jun-2020",
                "notes": "In August 2019, initial data from the phase I/II study (NCT04060342) in combination with GB-1275 in selected advanced solid tumors were expected in 2H20 [<ulink linkType=\"Reference\" linkID=\"2216818\">2216818</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "13-Feb-2020",
                "milestoneExtendedDate": "",
                "notes": "In February 2020, results from combination arm (part B) of phase II trial (NCT02325557; KEYNOTE-046) in patients with metastatic, castrate-resistant prostate cancer were reported [<ulink linkType=\"Reference\" linkID=\"2244960\">2244960</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, Cohort C results were presented at the virtual 2020 ESMO Congress. In RECIST-measurable population (n = 40), non-measurable (n = 61) and total population (n = 101), confirmed PSA, confirmed PSA response rate (primary endpoint) was 22.5, 21.3 and 21.8%, respectively. Kaplan-Meier estimate of confirmed median time to PSA progression was 3.5 months. In RECIST measurable (n = 25), non-measurable (n = 44) and total population (n = 69), disease control rate was 32.0, 36.4 and 34.8%, respectively. In RECIST-measurable population, overall response rate was 12.0%; CR was observed in 8% patients and partial response in 4% patients. Median radiographic PFS and OS (secondary endpoints) was 6.1 and 20.4 months, respectively. Median time to radiographic bone progression, radiographic soft tissue progression and symptomatic skeletal-related event were 8.3, 15.2 months and not-reached, respectively [<ulink linkType=\"Reference\" linkID=\"2324944\">2324944</ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "03-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, a phase III trial (NCT03834506) of drug in combination with chemotherapy compared to chemotherapy did not meet primary endpoints [ <ulink linkID=\"2713326\" linkType=\"Reference\">  2713326  </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "03-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, data from a phase III trial (NCT03834506) of drug in combination with chemotherapy compared to chemotherapy alone were reported from metastatic castration resistant prostate cancer patients  [ <ulink linkID=\"2713326\" linkType=\"Reference\">  2713326 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Mar-2023",
                "milestoneExtendedDate": "31-Mar-2023",
                "notes": "In October 2019, a phase I/II trial (NCT04060342) in combination with GB-1275 in advanced solid tumors was expected to complete in March 2023 [<ulink linkType=\"Reference\" linkID=\"2185368\">2185368</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3246",
              "name": "Hormone refractory prostate cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Jul-2016",
            "endDate": "15-Oct-2027",
            "statusDate": "02-May-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "3.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Jul-2016",
                "endDate": "02-May-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-May-2019",
                "endDate": "15-Oct-2026",
                "successPercentage": "5%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Oct-2026",
                "endDate": "11-Sep-2027",
                "successPercentage": "95%",
                "predictedDateL50": "04-Apr-2026",
                "predictedDateU50": "31-Jan-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Sep-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-May-2027",
                "predictedDateU50": "15-Oct-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "30-Jun-2020",
                "notes": "In August 2019, initial data from the phase I/II study (NCT04060342) in combination with GB-1275 in selected advanced solid tumors were expected in 2H20 [<ulink linkType=\"Reference\" linkID=\"2216818\">2216818</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, Cohort C results were presented at the virtual 2020 ESMO Congress. In RECIST-measurable population (n = 40), non-measurable (n = 61) and total population (n = 101), confirmed PSA, confirmed PSA response rate (primary endpoint) was 22.5, 21.3 and 21.8%, respectively. Kaplan-Meier estimate of confirmed median time to PSA progression was 3.5 months. In RECIST measurable (n = 25), non-measurable (n = 44) and total population (n = 69), disease control rate was 32.0, 36.4 and 34.8%, respectively. In RECIST-measurable population, overall response rate was 12.0%; CR was observed in 8% patients and partial response in 4% patients. Median radiographic PFS and OS (secondary endpoints) was 6.1 and 20.4 months, respectively. Median time to radiographic bone progression, radiographic soft tissue progression and symptomatic skeletal-related event were 8.3, 15.2 months and not-reached, respectively [<ulink linkType=\"Reference\" linkID=\"2324944\">2324944</ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "03-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, a phase III trial (NCT03834506) of drug in combination with chemotherapy compared to chemotherapy did not meet primary endpoints [ <ulink linkID=\"2713326\" linkType=\"Reference\">  2713326  </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "03-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, data from a phase III trial (NCT03834506) of drug in combination with chemotherapy compared to chemotherapy alone were reported from metastatic castration resistant prostate cancer patients [ <ulink linkID=\"2713326\" linkType=\"Reference\">  2713326 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Mar-2023",
                "milestoneExtendedDate": "31-Mar-2023",
                "notes": "In October 2019, a phase I/II trial (NCT04060342) in combination with GB-1275 in advanced solid tumors was expected to complete in March 2023 [<ulink linkType=\"Reference\" linkID=\"2185368\">2185368</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Sep-2025",
                "milestoneExtendedDate": "",
                "notes": "In December 2018, the phase I trial was expected to complete in September 2025 [<ulink linkType=\"Reference\" linkID=\"2114250\">2114250</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3378",
              "name": "Soft tissue sarcoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Mar-2015",
            "endDate": "",
            "statusDate": "01-May-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Mar-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3378",
              "name": "Soft tissue sarcoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Mar-2015",
            "endDate": "",
            "statusDate": "10-Jul-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Mar-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3466",
              "name": "Metastatic bladder cancer"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Oct-2014",
            "endDate": "",
            "statusDate": "31-Dec-2014",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "22-Oct-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3471",
              "name": "Metastatic brain cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Oct-2016",
            "endDate": "",
            "statusDate": "31-Oct-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Oct-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "24-May-2019",
            "endDate": "09-May-2032",
            "statusDate": "24-May-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "49%",
            "timeToRegistration": "8.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "24-May-2019",
                "endDate": "24-Jan-2031",
                "successPercentage": "52%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "11.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "24-Jan-2031",
                "endDate": "08-Mar-2032",
                "successPercentage": "95%",
                "predictedDateL50": "03-Jul-2030",
                "predictedDateU50": "08-Apr-2031",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-Mar-2032",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Oct-2031",
                "predictedDateU50": "09-May-2032",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "24-Jan-2031",
                "milestoneExtendedDate": "",
                "notes": "In May 2019, a phase III trial for the treatment of high-risk early-stage ER+/HER2- breast cancer was expected to complete in January 2031 in China [<ulink linkType=\"Reference\" linkID=\"2159678\">2159678</ulink>], [<ulink linkType=\"Reference\" linkID=\"2104003\">2104003</ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU (FR, NL)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "26-Jan-2021",
            "statusDate": "13-Sep-2019",
            "phaseHighestStatus": "Reg",
            "probabilityOfSuccess": null,
            "timeToRegistration": "-2.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "30-Nov-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "30-Nov-2015",
                "endDate": "11-Dec-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "11-Dec-2020",
                "endDate": "26-Jan-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Jan-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-May-2019",
                "milestoneExtendedDate": "31-May-2019",
                "notes": "In March 2019, a phase I trial, CATRIPCA, in patients with non-MSI-high advanced/metastatic pancreatic ductal adenocarcinoma or colorectal cancer was expected to begin in May 2019 [<ulink linkType=\"Reference\" linkID=\"2129404\">2129404</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "02-Apr-2020",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, positive interim data from the KEYNOTE-177 study, which evaluated pembrolizumab versus chemotherapy in first-line MSI-H or dMMR stage IV colorectal cancer, were reported. The trial met its co-primary endpoint of improved PFS, and the study would continue without changes to evaluate OS, the other co-primary endpoint [<ulink linkType=\"Reference\" linkID=\"2262094\">2262094</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "29-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, positive data were reported for the phase I trial (NCT03274804) in patients with refractory microsatellite stable metastatic colorectal cancer which showed that the trial met its co-primary endpoints [<ulink linkType=\"Reference\" linkID=\"2284169\">2284169</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "29-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, topline results from phase I trial (NCT03274804) in patients with refractory microsatellite stable metastatic colorectal cancer were presented [<ulink linkType=\"Reference\" linkID=\"2284169\">2284169</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "17-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, positive topline data were presented from phase I/II (NCT03168139; OPERA; EudraCT 2016-003657-15). CXCL 12 neutralization increase by NOX-A12 treatment, correlated with immune activation and clinical benefit. In tissue responders, increased T cells in liver metastases were also accompanied by specific cytokine patterns. Increased T-cells clustering in tumor biopsy tissue of tissue responders but not non-responders following anti-CXCL2 therapy was evidenced on tissue distribution/proximity analysis. In patients treated with NOX-A-12 + pembrolizumab combination therapy, median PFS was 1.87 months; OS was 39 and 20% at 6 and 12 months, respectively. The AE profile in the study was found to be similar with the safety profile for pembrolizumab or typical for the underlying diseases colorectal and pancreatic cancer.</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "17-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, positive topline data were presented from phase I/II (NCT03168139; OPERA; EudraCT 2016-003657-15). CXCL 12 neutralization increase by NOX-A12 treatment, correlated with immune activation and clinical benefit. In tissue responders, increased T cells in liver metastases were also accompanied by specific cytokine patterns. Increased T-cells clustering in tumor biopsy tissue of tissue responders but not non-responders following anti-CXCL2 therapy was evidenced on tissue distribution/proximity analysis. In patients treated with NOX-A-12 + pembrolizumab combination therapy, median PFS was 1.87 months; OS was 39 and 20% at 6 and 12 months, respectively. The AE profile in the study was found to be similar with the safety profile for pembrolizumab or typical for the underlying diseases colorectal and pancreatic cancer.</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, positive topline data were presented from phase I/II (NCT03168139; OPERA; EudraCT 2016-003657-15). CXCL 12 neutralization increase by NOX-A12 treatment, correlated with immune activation and clinical benefit. In tissue responders, increased T cells in liver metastases were also accompanied by specific cytokine patterns. Increased T-cells clustering in tumor biopsy tissue of tissue responders but not non-responders following anti-CXCL2 therapy was evidenced on tissue distribution/proximity analysis. In patients treated with NOX-A-12 + pembrolizumab combination therapy, median PFS was 1.87 months; OS was 39 and 20% at 6 and 12 months, respectively. The AE profile in the study was found to be similar with the safety profile for pembrolizumab or typical for the underlying diseases colorectal and pancreatic cancer.</para>",
                "newMilestone": false
              },
              {
                "title": "CHMP Opinion",
                "status": "Positive Opinion",
                "milestoneDate": "11-Dec-2020",
                "milestoneExtendedDate": "",
                "notes": "By December 2020, a filing had been made for the approval of pembrolizumab as first-line treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. In December 2020, the EMA's CHMP adopted a positive opinion for the approval in that setting.  The recommendation was based on the results of the phase III KEYNOTE-177 trial. At that time, a final EC decision was expected in 1Q21[<ulink linkType=\"Reference\" linkID=\"2377529\">2377529</ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Mar-2021",
                "notes": "By December 2020, a filing had been made for the approval of pembrolizumab as first-line treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. In December 2020, the EMA's CHMP adopted a positive opinion for the approval in that setting.  The recommendation was based on the results of the phase III KEYNOTE-177 trial. At that time, a final EC decision was expected in 1Q21[<ulink linkType=\"Reference\" linkID=\"2377529\">2377529</ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "FR",
              " NL"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "",
            "statusDate": "30-Nov-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "30-Nov-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "30-Nov-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Nov-2015",
            "endDate": "",
            "statusDate": "30-Nov-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "30-Nov-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-May-2015",
            "endDate": "",
            "statusDate": "16-Feb-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "11-May-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Sakigake",
            "startDate": "07-May-2013",
            "endDate": "",
            "statusDate": "15-May-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "07-May-2013",
                "endDate": "11-May-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "11-May-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-May-2015",
            "endDate": "",
            "statusDate": "15-May-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "11-May-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-May-2015",
            "endDate": "",
            "statusDate": "15-May-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "11-May-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "07-Mar-2022",
            "statusDate": "07-Mar-2022",
            "phaseHighestStatus": "Reg",
            "probabilityOfSuccess": null,
            "timeToRegistration": "-1.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "11-May-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "11-May-2015",
                "endDate": "07-Mar-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Mar-2022",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR",
              " KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-May-2015",
            "endDate": "",
            "statusDate": "15-May-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "11-May-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3669",
              "name": "Metastatic pancreas cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "",
            "statusDate": "10-Apr-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "10-Apr-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "10-Apr-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "",
            "statusDate": "18-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "18-Mar-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "18-Mar-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3769",
              "name": "Anaplastic thyroid cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Feb-2022",
            "endDate": "15-Jun-2028",
            "statusDate": "20-Oct-2016",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-Feb-2022",
                "endDate": "01-Dec-2024",
                "successPercentage": "23%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Dec-2024",
                "endDate": "16-Aug-2027",
                "successPercentage": "20%",
                "predictedDateL50": "30-Apr-2024",
                "predictedDateU50": "22-Mar-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-Aug-2027",
                "endDate": "15-May-2028",
                "successPercentage": "95%",
                "predictedDateL50": "28-Jun-2026",
                "predictedDateU50": "24-Jan-2028",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-May-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Feb-2028",
                "predictedDateU50": "15-Jun-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3788",
              "name": "Uveal melanoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (SE)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Feb-2018",
            "endDate": "16-Jun-2030",
            "statusDate": "21-Feb-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "7%",
            "timeToRegistration": "6.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "21-Feb-2018",
                "endDate": "30-Sep-2026",
                "successPercentage": "58%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "30-Sep-2026",
                "endDate": "20-Jun-2029",
                "successPercentage": "13%",
                "predictedDateL50": "22-Feb-2026",
                "predictedDateU50": "14-May-2027",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-Jun-2029",
                "endDate": "08-May-2030",
                "successPercentage": "95%",
                "predictedDateL50": "29-Apr-2028",
                "predictedDateU50": "28-Nov-2029",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-May-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Jan-2030",
                "predictedDateU50": "16-Jun-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "28-Sep-2019",
                "milestoneExtendedDate": "",
                "notes": "In September 2019, topline data of a phase II trial were presented [<ulink linkType=\"Reference\" linkID=\"2199176\">2199176</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "28-Sep-2019",
                "milestoneExtendedDate": "",
                "notes": "In September 2019, the primary endpoint of phase II trial was met [<ulink linkType=\"Reference\" linkID=\"2199176\">2199176</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "30-Apr-2022",
                "milestoneExtendedDate": "",
                "notes": "In March 2022, a phase II trial (NCT05282901) of pembrolizumab in combination with lenvatinib for metastatic uveal melanoma in France was planned to initiate in April 2022 [  <ulink linkID=\"2634768\" linkType=\"Reference\">  2634768 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Sep-2026",
                "milestoneExtendedDate": "",
                "notes": "In March 2022, a phase II trial (NCT05282901) of pembrolizumab in combination with lenvatinib for metastatic uveal melanoma in France was expected to complete in September 2026 [  <ulink linkID=\"2634768\" linkType=\"Reference\">  2634768 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "SE"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "30-Jun-2026",
            "statusDate": "18-Dec-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "42%",
            "timeToRegistration": "2.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "05-May-2016",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "05-May-2016",
                "endDate": "18-Dec-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "18-Dec-2018",
                "endDate": "08-Aug-2025",
                "successPercentage": "44%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Aug-2025",
                "endDate": "30-May-2026",
                "successPercentage": "95%",
                "predictedDateL50": "01-Apr-2025",
                "predictedDateU50": "28-Nov-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-May-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Feb-2026",
                "predictedDateU50": "30-Jun-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "20-Jul-2019",
                "milestoneExtendedDate": "",
                "notes": "In July 2019, primary endpoints of a phase II trial in Japanese patients were met [<ulink linkType=\"Reference\" linkID=\"2209224\">2209224</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Jul-2019",
                "milestoneExtendedDate": "",
                "notes": "In July 2019, interim data of a phase II trial was presented [<ulink linkType=\"Reference\" linkID=\"2209224\">2209224</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Nov-2024",
                "milestoneExtendedDate": "",
                "notes": "In November 2021, a phase II trial with pembrolizumab, bevacizumab, and platinum-based chemotherapy followed by pembrolizumab, bevacizumab, and olaparib in combination with platinum-sensitive recurrent ovarian cancer patients was expected to complete in November 2024 [ <ulink linkID=\"2610852\" linkType=\"Reference\">  2610852 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "08-Aug-2025",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, the randomized, phase III trial (NCT03740165; MK-7339-001/KEYLYNK-001/ENGOT-ov43) assessing first-line treatment using carboplatin/paclitaxel plus pembrolizumab and maintenance olaparib in women (expected n = 1086) with BRCA non-mutated advanced, epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer was expected to complete in August 2025 [<ulink linkType=\"Reference\" linkID=\"2169047\">2169047</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Apr-2022",
            "endDate": "28-Jul-2028",
            "statusDate": "28-Apr-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "8%",
            "timeToRegistration": "4.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "28-Apr-2022",
                "endDate": "28-Oct-2024",
                "successPercentage": "41%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "28-Oct-2024",
                "endDate": "20-Jul-2027",
                "successPercentage": "20%",
                "predictedDateL50": "04-Mar-2024",
                "predictedDateU50": "13-Feb-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-Jul-2027",
                "endDate": "19-Jun-2028",
                "successPercentage": "95%",
                "predictedDateL50": "25-May-2026",
                "predictedDateU50": "25-Dec-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Jun-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-Mar-2028",
                "predictedDateU50": "28-Jul-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "31-Mar-2028",
            "statusDate": "14-Aug-2015",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "8%",
            "timeToRegistration": "4.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "14-Aug-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "14-Aug-2015",
                "endDate": "15-Aug-2024",
                "successPercentage": "43%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "9.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "15-Aug-2024",
                "endDate": "14-May-2027",
                "successPercentage": "19%",
                "predictedDateL50": "13-Feb-2024",
                "predictedDateU50": "16-Dec-2024",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "14-May-2027",
                "endDate": "01-Mar-2028",
                "successPercentage": "95%",
                "predictedDateL50": "18-Mar-2026",
                "predictedDateU50": "25-Oct-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Mar-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Nov-2027",
                "predictedDateU50": "31-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In February 2019, a US phase I/II trial was planned for later in 2019 to evaluate pembrolizumab with Torque’s TRQ-1501 as a single agent and in combination standard-of-care relapsed or refractory advanced or metastatic ovarian cancer [<ulink linkType=\"Reference\" linkID=\"2121208\">2121208</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "27-Aug-2026",
            "statusDate": "18-Dec-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "40%",
            "timeToRegistration": "2.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "05-May-2016",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "05-May-2016",
                "endDate": "18-Dec-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "18-Dec-2018",
                "endDate": "08-Aug-2025",
                "successPercentage": "42%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Aug-2025",
                "endDate": "17-Jul-2026",
                "successPercentage": "95%",
                "predictedDateL50": "21-Mar-2025",
                "predictedDateU50": "28-Dec-2025",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Jul-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "27-Mar-2026",
                "predictedDateU50": "27-Aug-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "08-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "Source Date: 8/6/2021; Phase: C2;  In June 2021, it was reported that primary endpoint was met with complete debulking rate of 70 and 73.8%; overall response rate was 62.1 and 73.3% in arms 1 and 2, respectively [2469032].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "08-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "Source Date: 8/6/2021; Phase: C2;  In June 2021, it was reported that primary endpoint was met with complete debulking rate of 70 and 73.8%; overall response rate was 62.1 and 73.3% in arms 1 and 2, respectively [2469032].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "08-Aug-2025",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, the randomized, phase III trial (NCT03740165; MK-7339-001/KEYLYNK-001/ENGOT-ov43) assessing first-line treatment using carboplatin/paclitaxel plus pembrolizumab and maintenance olaparib in women (expected n = 1086) with BRCA non-mutated advanced, epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer was expected to complete in August 2025 [<ulink linkType=\"Reference\" linkID=\"2169047\">2169047</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3948",
              "name": "Inflammatory breast cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "26-Jan-2017",
            "endDate": "",
            "statusDate": "26-Jan-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "26-Jan-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "4250",
              "name": "Metastatic renal cell carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Jun-2023",
            "endDate": "07-Feb-2027",
            "statusDate": "12-Jun-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "50%",
            "timeToRegistration": "3.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "12-Jun-2023",
                "endDate": "07-Nov-2025",
                "successPercentage": "53%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Nov-2025",
                "endDate": "10-Dec-2026",
                "successPercentage": "95%",
                "predictedDateL50": "19-Oct-2024",
                "predictedDateU50": "26-Mar-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Dec-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-Aug-2026",
                "predictedDateU50": "07-Feb-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "4250",
              "name": "Metastatic renal cell carcinoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2016",
            "endDate": "",
            "statusDate": "30-Sep-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "30-Sep-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "4299",
              "name": "Salivary gland cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2014",
            "endDate": "",
            "statusDate": "06-Jun-2022",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Feb-2014",
                "endDate": "18-Dec-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "18-Dec-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "10408",
              "name": "Recurrent respiratory papillomatosis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Apr-2016",
            "endDate": "",
            "statusDate": "12-Apr-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Apr-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "24019",
              "name": "MSD KK"
            },
            "indication": {
              "id": "1750",
              "name": "Primary mediastinal large B-cell lymphoma"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "26-Jun-2020",
            "endDate": "04-Feb-2024",
            "statusDate": "05-Dec-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "26-Jun-2020",
                "endDate": "05-Dec-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Dec-2022",
                "endDate": "05-Jan-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Jan-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Dec-2023",
                "predictedDateU50": "04-Feb-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "sNDA/sBLA Filing",
                "status": "Filed",
                "milestoneDate": "05-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, sNDA was filed for primary mediastinal large B-cell lymphoma (PMBCL). At that time, the company submitted a partial change approval application [ <ulink linkID=\"2797241\" linkType=\"Reference\">  2797241 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "101102",
        "displayName": "retifanlimab",
        "drugPrograms": [
          {
            "company": {
              "id": "1101935",
              "name": "Zai Lab Ltd"
            },
            "indication": {
              "id": "725",
              "name": "Solid tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-Jul-2020",
            "endDate": "",
            "statusDate": "07-Jul-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "07-Jul-2020",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1101935",
              "name": "Zai Lab Ltd"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Nov-2016",
            "endDate": "07-Oct-2026",
            "statusDate": "21-Jun-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "62%",
            "timeToRegistration": "2.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "15-Nov-2016",
                "endDate": "21-Jun-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-Jun-2020",
                "endDate": "01-Aug-2025",
                "successPercentage": "65%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-Aug-2025",
                "endDate": "17-Aug-2026",
                "successPercentage": "95%",
                "predictedDateL50": "18-Apr-2025",
                "predictedDateU50": "05-Oct-2025",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Aug-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Apr-2026",
                "predictedDateU50": "07-Oct-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "13-Feb-2020",
                "milestoneExtendedDate": "",
                "notes": "In February 2020, an implied trial approval was granted for metastatic non-small cell lung cancer, MSI-H or dMMR endometrial cancer and HER-positive metastatic or locally advanced gastric cancer or gastroesophageal junction in China [ <ulink linkID=\"2241125\" linkType=\"Reference\">  2241125 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In March 2020, the first patient enrollment was expected in 2H20 in China [ <ulink linkID=\"2256891\" linkType=\"Reference\">  2256891 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Aug-2024",
                "milestoneExtendedDate": "31-Aug-2024",
                "notes": "In December 2019, a phase III trial for metastatic squamous and nonsquamous NSCLC was expected to complete in August 2024 [ <ulink linkID=\"2257010\" linkType=\"Reference\">  2257010 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "194",
              "name": "Sarcoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (FR, FR)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Mar-2022",
            "endDate": "05-Jan-2028",
            "statusDate": "03-Mar-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "20%",
            "timeToRegistration": "4.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "03-Mar-2022",
                "endDate": "15-Sep-2024",
                "successPercentage": "46%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "15-Sep-2024",
                "endDate": "31-Jan-2027",
                "successPercentage": "46%",
                "predictedDateL50": "05-Apr-2024",
                "predictedDateU50": "15-Dec-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Jan-2027",
                "endDate": "29-Nov-2027",
                "successPercentage": "95%",
                "predictedDateL50": "21-Jan-2026",
                "predictedDateU50": "21-Jun-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-Nov-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-Aug-2027",
                "predictedDateU50": "05-Jan-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Sep-2024",
                "milestoneExtendedDate": "30-Sep-2024",
                "notes": "In July 2021, a phase II trial (NCT04968106) was expected to complete in September 2024 in patients with selected retroperitoneal sarcoma [2522137].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "FR",
              " FR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "194",
              "name": "Sarcoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "06-Oct-2020",
            "endDate": "07-Jul-2027",
            "statusDate": "06-Oct-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "18%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "06-Oct-2020",
                "endDate": "06-May-2024",
                "successPercentage": "43%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "06-May-2024",
                "endDate": "21-Sep-2026",
                "successPercentage": "44%",
                "predictedDateL50": "11-Jan-2024",
                "predictedDateU50": "06-Aug-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Sep-2026",
                "endDate": "29-May-2027",
                "successPercentage": "95%",
                "predictedDateL50": "11-Sep-2025",
                "predictedDateU50": "09-Feb-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Mar-2027",
                "predictedDateU50": "07-Jul-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "29-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, a phase II trial (NCT04577014) in patients with sarcoma was expected to complete in September 2022 [ <ulink linkID=\"2337698\" linkType=\"Reference\">  2337698 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "307",
              "name": "Squamous cell carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Feb-2015",
            "endDate": "",
            "statusDate": "26-Feb-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Feb-2015",
                "endDate": "27-Sep-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "27-Sep-2020",
                "endDate": "26-Feb-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Feb-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "307",
              "name": "Squamous cell carcinoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Oct-2022",
            "endDate": "29-Aug-2027",
            "statusDate": "12-Oct-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "31%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Oct-2022",
                "endDate": "16-Oct-2024",
                "successPercentage": "63%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Oct-2024",
                "endDate": "02-Nov-2026",
                "successPercentage": "51%",
                "predictedDateL50": "19-Mar-2024",
                "predictedDateU50": "01-Feb-2025",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-Nov-2026",
                "endDate": "25-Jul-2027",
                "successPercentage": "95%",
                "predictedDateL50": "14-Dec-2025",
                "predictedDateU50": "08-Mar-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Apr-2027",
                "predictedDateU50": "29-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Sep-2024",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, a phase II trial (NCT05287113) was expected to complete in September 2024 [ <ulink linkID=\"2635195\" linkType=\"Reference\">  2635195 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "307",
              "name": "Squamous cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US, US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Feb-2015",
            "endDate": "",
            "statusDate": "21-Jan-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Feb-2015",
                "endDate": "27-Sep-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "27-Sep-2020",
                "endDate": "21-Jan-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Jan-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US",
              " US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "793",
              "name": "Mouth tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Oct-2022",
            "endDate": "05-Nov-2027",
            "statusDate": "12-Oct-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "33%",
            "timeToRegistration": "3.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Oct-2022",
                "endDate": "03-Dec-2024",
                "successPercentage": "66%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "03-Dec-2024",
                "endDate": "01-Jan-2027",
                "successPercentage": "53%",
                "predictedDateL50": "10-Apr-2024",
                "predictedDateU50": "11-Apr-2025",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-Jan-2027",
                "endDate": "05-Oct-2027",
                "successPercentage": "95%",
                "predictedDateL50": "06-Feb-2026",
                "predictedDateU50": "07-May-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Oct-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Jul-2027",
                "predictedDateU50": "05-Nov-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Sep-2024",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, a phase II trial (NCT05287113) was expected to complete in September 2024 [ <ulink linkID=\"2635195\" linkType=\"Reference\">  2635195 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "793",
              "name": "Mouth tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Oct-2022",
            "endDate": "25-Mar-2028",
            "statusDate": "12-Oct-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "31%",
            "timeToRegistration": "4.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Oct-2022",
                "endDate": "03-Dec-2024",
                "successPercentage": "64%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "03-Dec-2024",
                "endDate": "24-May-2027",
                "successPercentage": "51%",
                "predictedDateL50": "10-Apr-2024",
                "predictedDateU50": "11-Apr-2025",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "24-May-2027",
                "endDate": "22-Feb-2028",
                "successPercentage": "95%",
                "predictedDateL50": "28-Apr-2026",
                "predictedDateU50": "11-Oct-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Feb-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "20-Nov-2027",
                "predictedDateU50": "25-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Sep-2024",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, a phase II trial (NCT05287113) was expected to complete in September 2024 [ <ulink linkID=\"2635195\" linkType=\"Reference\">  2635195 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "793",
              "name": "Mouth tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Oct-2022",
            "endDate": "21-May-2028",
            "statusDate": "12-Oct-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "33%",
            "timeToRegistration": "4.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Oct-2022",
                "endDate": "03-Dec-2024",
                "successPercentage": "66%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "03-Dec-2024",
                "endDate": "24-May-2027",
                "successPercentage": "53%",
                "predictedDateL50": "10-Apr-2024",
                "predictedDateU50": "11-Apr-2025",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "24-May-2027",
                "endDate": "12-Apr-2028",
                "successPercentage": "95%",
                "predictedDateL50": "28-Apr-2026",
                "predictedDateU50": "11-Oct-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Apr-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Jan-2028",
                "predictedDateU50": "21-May-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Sep-2024",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, a phase II trial (NCT05287113) was expected to complete in September 2024 [ <ulink linkID=\"2635195\" linkType=\"Reference\">  2635195 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "794",
              "name": "Pharynx tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Oct-2022",
            "endDate": "30-Nov-2027",
            "statusDate": "12-Oct-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "36%",
            "timeToRegistration": "3.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Oct-2022",
                "endDate": "25-Dec-2024",
                "successPercentage": "72%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "25-Dec-2024",
                "endDate": "23-Jan-2027",
                "successPercentage": "53%",
                "predictedDateL50": "15-Apr-2024",
                "predictedDateU50": "30-Apr-2025",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-Jan-2027",
                "endDate": "31-Oct-2027",
                "successPercentage": "95%",
                "predictedDateL50": "28-Feb-2026",
                "predictedDateU50": "29-May-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "31-Oct-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Jul-2027",
                "predictedDateU50": "30-Nov-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Sep-2024",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, a phase II trial (NCT05287113) was expected to complete in September 2024 [ <ulink linkID=\"2635195\" linkType=\"Reference\">  2635195 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "794",
              "name": "Pharynx tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Oct-2022",
            "endDate": "18-Apr-2028",
            "statusDate": "12-Oct-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "34%",
            "timeToRegistration": "4.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Oct-2022",
                "endDate": "25-Dec-2024",
                "successPercentage": "71%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "25-Dec-2024",
                "endDate": "15-Jun-2027",
                "successPercentage": "51%",
                "predictedDateL50": "15-Apr-2024",
                "predictedDateU50": "30-Apr-2025",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Jun-2027",
                "endDate": "18-Mar-2028",
                "successPercentage": "95%",
                "predictedDateL50": "20-May-2026",
                "predictedDateU50": "02-Nov-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "18-Mar-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-Dec-2027",
                "predictedDateU50": "18-Apr-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Sep-2024",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, a phase II trial (NCT05287113) was expected to complete in September 2024 [ <ulink linkID=\"2635195\" linkType=\"Reference\">  2635195 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "794",
              "name": "Pharynx tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Oct-2022",
            "endDate": "14-Jun-2028",
            "statusDate": "12-Oct-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "36%",
            "timeToRegistration": "4.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Oct-2022",
                "endDate": "25-Dec-2024",
                "successPercentage": "72%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "25-Dec-2024",
                "endDate": "15-Jun-2027",
                "successPercentage": "53%",
                "predictedDateL50": "15-Apr-2024",
                "predictedDateU50": "30-Apr-2025",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Jun-2027",
                "endDate": "10-May-2028",
                "successPercentage": "95%",
                "predictedDateL50": "20-May-2026",
                "predictedDateU50": "02-Nov-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-May-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Jan-2028",
                "predictedDateU50": "14-Jun-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Sep-2024",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, a phase II trial (NCT05287113) was expected to complete in September 2024 [ <ulink linkID=\"2635195\" linkType=\"Reference\">  2635195 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "1240",
              "name": "Mesothelioma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Feb-2015",
            "endDate": "",
            "statusDate": "15-Jul-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Feb-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "1539",
              "name": "Vascular neoplasm"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Sep-2020",
            "endDate": "07-Sep-2027",
            "statusDate": "29-Sep-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "17%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "29-Sep-2020",
                "endDate": "21-Jun-2024",
                "successPercentage": "49%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-Jun-2024",
                "endDate": "11-Nov-2026",
                "successPercentage": "37%",
                "predictedDateL50": "21-Jan-2024",
                "predictedDateU50": "13-Oct-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "11-Nov-2026",
                "endDate": "05-Aug-2027",
                "successPercentage": "95%",
                "predictedDateL50": "30-Oct-2025",
                "predictedDateU50": "31-Mar-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Aug-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "06-May-2027",
                "predictedDateU50": "07-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "29-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, a phase II trial (NCT04577014) in patients with vasclar neoplasm was expected to complete in September 2022 [ <ulink linkID=\"2337698\" linkType=\"Reference\">  2337698 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "1101935",
              "name": "Zai Lab Ltd"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "26-Jan-2021",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (FR, IT)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Jan-2019",
            "endDate": "14-Jan-2028",
            "statusDate": "09-Dec-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "29%",
            "timeToRegistration": "4.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "09-Jan-2019",
                "endDate": "06-Sep-2024",
                "successPercentage": "67%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "06-Sep-2024",
                "endDate": "22-Jan-2027",
                "successPercentage": "46%",
                "predictedDateL50": "17-Feb-2024",
                "predictedDateU50": "29-Dec-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Jan-2027",
                "endDate": "02-Dec-2027",
                "successPercentage": "95%",
                "predictedDateL50": "12-Jan-2026",
                "predictedDateU50": "12-Jun-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Dec-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-Aug-2027",
                "predictedDateU50": "14-Jan-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Jun-2024",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a phase II trial (NCT04586244; Optimus) in patients with transitional cell urothelial carcinoma was expected to complete in June 2024 [  <ulink linkID=\"2344106\" linkType=\"Reference\">   2344106  </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "FR",
              " IT"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Jan-2019",
            "endDate": "19-Nov-2027",
            "statusDate": "09-Dec-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "27%",
            "timeToRegistration": "3.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "09-Jan-2019",
                "endDate": "06-Sep-2024",
                "successPercentage": "65%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "06-Sep-2024",
                "endDate": "22-Jan-2027",
                "successPercentage": "44%",
                "predictedDateL50": "17-Feb-2024",
                "predictedDateU50": "29-Dec-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Jan-2027",
                "endDate": "16-Oct-2027",
                "successPercentage": "95%",
                "predictedDateL50": "12-Jan-2026",
                "predictedDateU50": "12-Jun-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "16-Oct-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-Jul-2027",
                "predictedDateU50": "19-Nov-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "1791",
              "name": "Penis tumor"
            },
            "country": {
              "id": "EU",
              "name": "EU (DE, IT)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Apr-2020",
            "endDate": "24-Oct-2027",
            "statusDate": "28-Apr-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "25%",
            "timeToRegistration": "3.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "28-Apr-2020",
                "endDate": "09-Jul-2024",
                "successPercentage": "55%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "09-Jul-2024",
                "endDate": "04-Dec-2026",
                "successPercentage": "48%",
                "predictedDateL50": "21-Jan-2024",
                "predictedDateU50": "01-Nov-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "04-Dec-2026",
                "endDate": "23-Sep-2027",
                "successPercentage": "95%",
                "predictedDateL50": "18-Nov-2025",
                "predictedDateU50": "24-Apr-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Sep-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Jun-2027",
                "predictedDateU50": "24-Oct-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Jan-2022",
                "notes": "In January 2020, a phase II trial (NCT04231981; ORPHEUS) in patients with advanced penile squamous cell carcinoma was planned to complete in January 2022 [ <ulink linkID=\"2238426\" linkType=\"Reference\">  2238426 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "DE",
              " IT"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "2193",
              "name": "Anal tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "08-Oct-2018",
            "endDate": "",
            "statusDate": "21-Jan-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "08-Oct-2018",
                "endDate": "31-Aug-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "31-Aug-2020",
                "endDate": "21-Jan-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Jan-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "2193",
              "name": "Anal tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "10-Sep-2018",
            "endDate": "",
            "statusDate": "09-Nov-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "10-Sep-2018",
                "endDate": "09-Nov-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "09-Nov-2020",
                "endDate": "26-Feb-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Feb-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "2380",
              "name": "Bladder cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU (FR, IT)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Dec-2021",
            "endDate": "25-Oct-2027",
            "statusDate": "09-Dec-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "22%",
            "timeToRegistration": "3.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "09-Dec-2021",
                "endDate": "30-Jun-2024",
                "successPercentage": "54%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "30-Jun-2024",
                "endDate": "01-Nov-2026",
                "successPercentage": "43%",
                "predictedDateL50": "22-Jan-2024",
                "predictedDateU50": "17-Sep-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-Nov-2026",
                "endDate": "14-Sep-2027",
                "successPercentage": "95%",
                "predictedDateL50": "01-Nov-2025",
                "predictedDateU50": "28-Mar-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Sep-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-Jun-2027",
                "predictedDateU50": "25-Oct-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Jun-2024",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a phase II trial (NCT04586244; Optimus) in patients with transitional cell urothelial carcinoma was expected to complete in June 2024 [  <ulink linkID=\"2344106\" linkType=\"Reference\">   2344106  </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "FR",
              " IT"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "2380",
              "name": "Bladder cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Dec-2021",
            "endDate": "29-Aug-2027",
            "statusDate": "09-Dec-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "20%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "09-Dec-2021",
                "endDate": "28-Jun-2024",
                "successPercentage": "52%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "28-Jun-2024",
                "endDate": "31-Oct-2026",
                "successPercentage": "41%",
                "predictedDateL50": "20-Jan-2024",
                "predictedDateU50": "15-Sep-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Oct-2026",
                "endDate": "27-Jul-2027",
                "successPercentage": "95%",
                "predictedDateL50": "26-Oct-2025",
                "predictedDateU50": "24-Mar-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Apr-2027",
                "predictedDateU50": "29-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "2445",
              "name": "Fibrosarcoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Sep-2020",
            "endDate": "26-Sep-2027",
            "statusDate": "29-Sep-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "17%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "29-Sep-2020",
                "endDate": "10-Jul-2024",
                "successPercentage": "50%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Jul-2024",
                "endDate": "30-Nov-2026",
                "successPercentage": "35%",
                "predictedDateL50": "23-Jan-2024",
                "predictedDateU50": "14-Nov-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2026",
                "endDate": "22-Aug-2027",
                "successPercentage": "95%",
                "predictedDateL50": "18-Nov-2025",
                "predictedDateU50": "19-Apr-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Aug-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-May-2027",
                "predictedDateU50": "26-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "29-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, a phase II trial (NCT04577014) in patients with fibrosarcoma was expected to complete in September 2022 [ <ulink linkID=\"2337698\" linkType=\"Reference\">  2337698 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "2446",
              "name": "Leiomyosarcoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Sep-2020",
            "endDate": "14-Jul-2027",
            "statusDate": "29-Sep-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "18%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "29-Sep-2020",
                "endDate": "09-May-2024",
                "successPercentage": "43%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "09-May-2024",
                "endDate": "29-Sep-2026",
                "successPercentage": "45%",
                "predictedDateL50": "14-Jan-2024",
                "predictedDateU50": "10-Aug-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Sep-2026",
                "endDate": "05-Jun-2027",
                "successPercentage": "95%",
                "predictedDateL50": "17-Sep-2025",
                "predictedDateU50": "16-Feb-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Mar-2027",
                "predictedDateU50": "14-Jul-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "29-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, a phase II trial (NCT04577014) in patients with leiomyosarcoma was expected to complete in September 2022 [ <ulink linkID=\"2337698\" linkType=\"Reference\">  2337698 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "2447",
              "name": "Liposarcoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Jun-2020",
            "endDate": "13-Sep-2027",
            "statusDate": "17-Jun-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "16%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "17-Jun-2020",
                "endDate": "02-Jul-2024",
                "successPercentage": "50%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-Jul-2024",
                "endDate": "17-Nov-2026",
                "successPercentage": "34%",
                "predictedDateL50": "11-Jan-2024",
                "predictedDateU50": "07-Nov-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-Nov-2026",
                "endDate": "10-Aug-2027",
                "successPercentage": "95%",
                "predictedDateL50": "07-Nov-2025",
                "predictedDateU50": "07-Apr-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Aug-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-May-2027",
                "predictedDateU50": "13-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "29-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, a phase II trial (NCT04577014) in patients with liposarcoma was expected to complete in September 2022 [ <ulink linkID=\"2337698\" linkType=\"Reference\">  2337698 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In June 2020, a phase II trial (NCT04438824) in liposarcoma patients was expected to complete in June 2023 [ <ulink linkID=\"2292092\" linkType=\"Reference\">  2292092 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "2454",
              "name": "Glioblastoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Apr-2020",
            "endDate": "26-Jul-2028",
            "statusDate": "20-Apr-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "16%",
            "timeToRegistration": "4.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "20-Apr-2020",
                "endDate": "15-Jun-2025",
                "successPercentage": "43%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "15-Jun-2025",
                "endDate": "09-Oct-2027",
                "successPercentage": "39%",
                "predictedDateL50": "23-Jan-2025",
                "predictedDateU50": "13-Sep-2025",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-Oct-2027",
                "endDate": "19-Jun-2028",
                "successPercentage": "93%",
                "predictedDateL50": "11-Oct-2026",
                "predictedDateU50": "24-Feb-2028",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Jun-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Mar-2028",
                "predictedDateU50": "26-Jul-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Other Outcome",
                "milestoneDate": "06-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, interim analysis data of a phase II study (NCT03532295) in 24 patients with recurrent glioblastoma were presented. The most commonly reported grade 1 to 2 TRAEs included increased ALT and TSH (21% each), increased AST (17%), hypoT4 and fatigue (13% each), arthralgia and pruritus (8% each), adrenal insufficiency, edema, weight loss, bacteremia, low WBC, low platelet count, nasusea, vomiting, diarrhea, increased AKP, elevated bilirubin, generalized weakness, dizziness, rash, urticaria, infusion site reaction and hypertension (4% each) and grade 3+ included myositis (4%). With a median follow-up of 15.03 months, median PFS was 7.6 months. Median OS was 12.2 months and month-9 OS rate was 70%. ORR was 54% [ <ulink linkID=\"2692028\" linkType=\"Reference\">  2692028 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In January 2020, the phase II trial (NCT04225039) was expected to complete in December 2024 [ <ulink linkID=\"2236950\" linkType=\"Reference\">  2236950 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Apr-2025",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, a phase II trial (NCT03532295) in patients with recurrent glioblastoma, was expected to complete in April 2025 [ <ulink linkID=\"2038757\" linkType=\"Reference\">  2038757 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2025",
                "milestoneExtendedDate": "30-Jun-2025",
                "notes": "In June 2020, the phase II trial (NCT04225039) was expected to complete in June 2025 [ <ulink linkID=\"2236950\" linkType=\"Reference\">  2236950 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "2819",
              "name": "Myxosarcoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Sep-2020",
            "endDate": "12-Sep-2027",
            "statusDate": "29-Sep-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "22%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "29-Sep-2020",
                "endDate": "21-Jun-2024",
                "successPercentage": "49%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-Jun-2024",
                "endDate": "16-Nov-2026",
                "successPercentage": "47%",
                "predictedDateL50": "21-Jan-2024",
                "predictedDateU50": "13-Oct-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-Nov-2026",
                "endDate": "09-Aug-2027",
                "successPercentage": "95%",
                "predictedDateL50": "31-Oct-2025",
                "predictedDateU50": "06-Apr-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Aug-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-May-2027",
                "predictedDateU50": "12-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "29-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, a phase II trial (NCT04577014) in patients with myxosarcoma was expected to complete in September 2022 [ <ulink linkID=\"2337698\" linkType=\"Reference\">  2337698 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3198",
              "name": "Larynx tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Oct-2022",
            "endDate": "05-Nov-2027",
            "statusDate": "12-Oct-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "38%",
            "timeToRegistration": "3.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Oct-2022",
                "endDate": "03-Dec-2024",
                "successPercentage": "75%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "03-Dec-2024",
                "endDate": "01-Jan-2027",
                "successPercentage": "53%",
                "predictedDateL50": "10-Apr-2024",
                "predictedDateU50": "11-Apr-2025",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-Jan-2027",
                "endDate": "05-Oct-2027",
                "successPercentage": "95%",
                "predictedDateL50": "06-Feb-2026",
                "predictedDateU50": "07-May-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Oct-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Jul-2027",
                "predictedDateU50": "05-Nov-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Sep-2024",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, a phase II trial (NCT05287113) was expected to complete in September 2024 [ <ulink linkID=\"2635195\" linkType=\"Reference\">  2635195 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3198",
              "name": "Larynx tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Oct-2022",
            "endDate": "25-Mar-2028",
            "statusDate": "12-Oct-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "35%",
            "timeToRegistration": "4.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Oct-2022",
                "endDate": "03-Dec-2024",
                "successPercentage": "73%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "03-Dec-2024",
                "endDate": "24-May-2027",
                "successPercentage": "51%",
                "predictedDateL50": "10-Apr-2024",
                "predictedDateU50": "11-Apr-2025",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "24-May-2027",
                "endDate": "22-Feb-2028",
                "successPercentage": "95%",
                "predictedDateL50": "28-Apr-2026",
                "predictedDateU50": "11-Oct-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Feb-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "20-Nov-2027",
                "predictedDateU50": "25-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Sep-2024",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, a phase II trial (NCT05287113) was expected to complete in September 2024 [ <ulink linkID=\"2635195\" linkType=\"Reference\">  2635195 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3198",
              "name": "Larynx tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Oct-2022",
            "endDate": "21-May-2028",
            "statusDate": "12-Oct-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "38%",
            "timeToRegistration": "4.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Oct-2022",
                "endDate": "03-Dec-2024",
                "successPercentage": "75%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "03-Dec-2024",
                "endDate": "24-May-2027",
                "successPercentage": "53%",
                "predictedDateL50": "10-Apr-2024",
                "predictedDateU50": "11-Apr-2025",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "24-May-2027",
                "endDate": "12-Apr-2028",
                "successPercentage": "95%",
                "predictedDateL50": "28-Apr-2026",
                "predictedDateU50": "11-Oct-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Apr-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Jan-2028",
                "predictedDateU50": "21-May-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Sep-2024",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, a phase II trial (NCT05287113) was expected to complete in September 2024 [ <ulink linkID=\"2635195\" linkType=\"Reference\">  2635195 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3256",
              "name": "Stage III melanoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Jul-2020",
            "endDate": "19-Jun-2027",
            "statusDate": "28-Jul-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "15%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "28-Jul-2020",
                "endDate": "12-May-2024",
                "successPercentage": "43%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "12-May-2024",
                "endDate": "01-Sep-2026",
                "successPercentage": "37%",
                "predictedDateL50": "11-Jan-2024",
                "predictedDateU50": "11-Aug-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-Sep-2026",
                "endDate": "13-May-2027",
                "successPercentage": "92%",
                "predictedDateL50": "31-Aug-2025",
                "predictedDateU50": "15-Jan-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-Feb-2027",
                "predictedDateU50": "19-Jun-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3257",
              "name": "Stage IV melanoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Jan-2019",
            "endDate": "25-Dec-2026",
            "statusDate": "19-Dec-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "26%",
            "timeToRegistration": "3.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "09-Jan-2019",
                "endDate": "10-Dec-2023",
                "successPercentage": "85%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "07-Mar-2026",
                "successPercentage": "34%",
                "predictedDateL50": "04-Jun-2023",
                "predictedDateU50": "20-May-2024",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Mar-2026",
                "endDate": "19-Nov-2026",
                "successPercentage": "89%",
                "predictedDateL50": "14-Mar-2025",
                "predictedDateU50": "26-Jul-2026",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Nov-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-Aug-2026",
                "predictedDateU50": "25-Dec-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Apr-2021",
                "milestoneExtendedDate": "30-Apr-2021",
                "notes": "In September 2018, the phase II trial (NCT03679767; POD1UM-203) was expected to complete in April 2021 [ <ulink linkID=\"2075214\" linkType=\"Reference\">  2075214 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "07-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, positive data were presented from a phase II study (NCT03679767) in patients with NSCLC, urothelial cancer, metastatic melanoma and RCC [ <ulink linkID=\"2474950\" linkType=\"Reference\">  2474950 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3257",
              "name": "Stage IV melanoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "19-Dec-2018",
            "endDate": "16-Feb-2027",
            "statusDate": "19-Dec-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "26%",
            "timeToRegistration": "3.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "19-Dec-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "86%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "07-Mar-2026",
                "successPercentage": "35%",
                "predictedDateL50": "04-Jun-2023",
                "predictedDateU50": "20-May-2024",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Mar-2026",
                "endDate": "05-Jan-2027",
                "successPercentage": "88%",
                "predictedDateL50": "14-Mar-2025",
                "predictedDateU50": "26-Jul-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Jan-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "27-Sep-2026",
                "predictedDateU50": "16-Feb-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Apr-2021",
                "milestoneExtendedDate": "30-Apr-2021",
                "notes": "In September 2018, the phase II trial (NCT03679767;POD1UM-203) was expected to complete in April 2021 [ <ulink linkID=\"2075214\" linkType=\"Reference\">  2075214 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "07-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, positive data were presented from a phase II study (NCT03679767) in patients with NSCLC, urothelial cancer, metastatic melanoma and RCC [ <ulink linkID=\"2474950\" linkType=\"Reference\">  2474950 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3378",
              "name": "Soft tissue sarcoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Feb-2015",
            "endDate": "",
            "statusDate": "29-Sep-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Feb-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3466",
              "name": "Metastatic bladder cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Feb-2015",
            "endDate": "",
            "statusDate": "19-Dec-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Feb-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3466",
              "name": "Metastatic bladder cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "19-Dec-2018",
            "endDate": "29-Mar-2027",
            "statusDate": "19-Dec-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "32%",
            "timeToRegistration": "3.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "19-Dec-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "85%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "04-Apr-2026",
                "successPercentage": "40%",
                "predictedDateL50": "19-Apr-2023",
                "predictedDateU50": "05-Jun-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "04-Apr-2026",
                "endDate": "16-Feb-2027",
                "successPercentage": "95%",
                "predictedDateL50": "06-Apr-2025",
                "predictedDateU50": "20-Aug-2026",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "16-Feb-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Nov-2026",
                "predictedDateU50": "29-Mar-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "07-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, positive data were presented from a phase II study (NCT03679767) in patients with NSCLC, urothelial cancer, metastatic melanoma and RCC [ <ulink linkID=\"2474950\" linkType=\"Reference\">  2474950 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Feb-2015",
            "endDate": "",
            "statusDate": "13-Jul-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Feb-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Feb-2015",
            "endDate": "10-May-2026",
            "statusDate": "27-Sep-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "52%",
            "timeToRegistration": "2.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Feb-2015",
                "endDate": "27-Sep-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "27-Sep-2020",
                "endDate": "01-Aug-2025",
                "successPercentage": "55%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-Aug-2025",
                "endDate": "04-Apr-2026",
                "successPercentage": "95%",
                "predictedDateL50": "11-Apr-2025",
                "predictedDateU50": "20-Oct-2025",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Apr-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "12-Jan-2026",
                "predictedDateU50": "10-May-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jan-2019",
                "milestoneExtendedDate": "31-Jan-2019",
                "notes": "In September 2018, the phase II trial was expected to begin in January 2019 [ <ulink linkID=\"2075214\" linkType=\"Reference\">  2075214 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Feb-2020",
                "milestoneExtendedDate": "29-Feb-2020",
                "notes": "In December 2019, a phase III trial for metastatic squamous and nonsquamous NSCLC was expected to start in February 2020 [ <ulink linkID=\"2257010\" linkType=\"Reference\">  2257010 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Apr-2021",
                "milestoneExtendedDate": "30-Apr-2021",
                "notes": "In September 2018, the phase II trial was expected to complete in April 2021 [ <ulink linkID=\"2075214\" linkType=\"Reference\">  2075214 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "07-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, positive data were presented from a phase II study (NCT03679767) in patients with NSCLC, urothelial cancer, metastatic melanoma and RCC [ <ulink linkID=\"2474950\" linkType=\"Reference\">  2474950 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Aug-2024",
                "milestoneExtendedDate": "31-Aug-2024",
                "notes": "In December 2019, a phase III trial for metastatic squamous and nonsquamous NSCLC was expected to complete in August 2024 [ <ulink linkID=\"2257010\" linkType=\"Reference\">  2257010 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Delayed",
                "milestoneDate": "01-Aug-2025",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, a phase III study (NCT04205812) was expected to complete in April 2025 [  <ulink linkID=\"2257010\" linkType=\"Reference\">  2257010  </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Nov-2016",
            "endDate": "28-Jul-2026",
            "statusDate": "27-Sep-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "54%",
            "timeToRegistration": "2.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "15-Nov-2016",
                "endDate": "19-Dec-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "19-Dec-2018",
                "endDate": "27-Sep-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "27-Sep-2020",
                "endDate": "01-Aug-2025",
                "successPercentage": "57%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-Aug-2025",
                "endDate": "17-Jun-2026",
                "successPercentage": "95%",
                "predictedDateL50": "11-Apr-2025",
                "predictedDateU50": "19-Oct-2025",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Jun-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "08-Mar-2026",
                "predictedDateU50": "28-Jul-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Apr-2021",
                "milestoneExtendedDate": "30-Apr-2021",
                "notes": "In September 2018, the phase II trial was expected to complete in April 2021 [ <ulink linkID=\"2075214\" linkType=\"Reference\">  2075214 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "07-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, positive data were presented from a phase II study (NCT03679767) in patients with NSCLC, urothelial cancer, metastatic melanoma and RCC [ <ulink linkID=\"2474950\" linkType=\"Reference\">  2474950 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Delayed",
                "milestoneDate": "01-Aug-2025",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, a phase III study (NCT04205812) was expected to complete in April 2025 [  <ulink linkID=\"2257010\" linkType=\"Reference\">  2257010  </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU (NL)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Feb-2015",
            "endDate": "",
            "statusDate": "29-Jul-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Feb-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "NL"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Feb-2015",
            "endDate": "17-Mar-2027",
            "statusDate": "30-Sep-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "24%",
            "timeToRegistration": "3.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Feb-2015",
                "endDate": "30-Sep-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "30-Sep-2019",
                "endDate": "16-May-2026",
                "successPercentage": "26%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-May-2026",
                "endDate": "11-Feb-2027",
                "successPercentage": "93%",
                "predictedDateL50": "27-Nov-2025",
                "predictedDateU50": "18-Sep-2026",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Feb-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Nov-2026",
                "predictedDateU50": "17-Mar-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-May-2026",
                "milestoneExtendedDate": "31-May-2026",
                "notes": "In September 2019, a phase II/III (NCT04082364; MAHOGANY) trial for HER2-positive gastric or gastroesophageal junction cancer was expected to complete in May 2026 [ <ulink linkID=\"2191890\" linkType=\"Reference\">  2191890 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU (NL)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Feb-2015",
            "endDate": "",
            "statusDate": "29-Jul-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Feb-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "NL"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3669",
              "name": "Metastatic pancreas cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Feb-2015",
            "endDate": "",
            "statusDate": "19-Mar-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Feb-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3673",
              "name": "Metastatic head and neck cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Oct-2022",
            "endDate": "29-Aug-2027",
            "statusDate": "12-Oct-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "31%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Oct-2022",
                "endDate": "16-Oct-2024",
                "successPercentage": "63%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Oct-2024",
                "endDate": "02-Nov-2026",
                "successPercentage": "51%",
                "predictedDateL50": "19-Mar-2024",
                "predictedDateU50": "01-Feb-2025",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-Nov-2026",
                "endDate": "25-Jul-2027",
                "successPercentage": "95%",
                "predictedDateL50": "14-Dec-2025",
                "predictedDateU50": "08-Mar-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Apr-2027",
                "predictedDateU50": "29-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Sep-2024",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, a phase II trial (NCT05287113) was expected to complete in September 2024 [ <ulink linkID=\"2635195\" linkType=\"Reference\">  2635195 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3673",
              "name": "Metastatic head and neck cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Aug-2021",
            "endDate": "06-Jan-2028",
            "statusDate": "12-Oct-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "26%",
            "timeToRegistration": "4.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "05-Aug-2021",
                "endDate": "12-Oct-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "12-Oct-2022",
                "endDate": "16-Oct-2024",
                "successPercentage": "61%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Oct-2024",
                "endDate": "14-Mar-2027",
                "successPercentage": "45%",
                "predictedDateL50": "19-Mar-2024",
                "predictedDateU50": "01-Feb-2025",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "14-Mar-2027",
                "endDate": "02-Dec-2027",
                "successPercentage": "95%",
                "predictedDateL50": "23-Feb-2026",
                "predictedDateU50": "31-Jul-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Dec-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Sep-2027",
                "predictedDateU50": "06-Jan-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Sep-2024",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, a phase II trial (NCT05287113) was expected to complete in September 2024 [ <ulink linkID=\"2635195\" linkType=\"Reference\">  2635195 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Dec-2024",
                "milestoneExtendedDate": "",
                "notes": "In July 2020, a phase Ib study (phase Ib) to evaluate DPV-001 + INCAGN-01876 + INCMGA-00012 in patients with head and neck squamous cell carcinoma was expected to be completed in July 2024 [ <ulink linkID=\"2372313\" linkType=\"Reference\">  2372313 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3673",
              "name": "Metastatic head and neck cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Oct-2022",
            "endDate": "07-Mar-2028",
            "statusDate": "12-Oct-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "29%",
            "timeToRegistration": "4.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Oct-2022",
                "endDate": "16-Oct-2024",
                "successPercentage": "63%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Oct-2024",
                "endDate": "20-Mar-2027",
                "successPercentage": "49%",
                "predictedDateL50": "19-Mar-2024",
                "predictedDateU50": "01-Feb-2025",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-Mar-2027",
                "endDate": "21-Jan-2028",
                "successPercentage": "95%",
                "predictedDateL50": "01-Mar-2026",
                "predictedDateU50": "05-Aug-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-Jan-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Oct-2027",
                "predictedDateU50": "07-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Sep-2024",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, a phase II trial (NCT05287113) was expected to complete in September 2024 [ <ulink linkID=\"2635195\" linkType=\"Reference\">  2635195 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Jul-2019",
            "endDate": "22-Feb-2029",
            "statusDate": "22-Jul-2019",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "35%",
            "timeToRegistration": "5.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "22-Jul-2019",
                "endDate": "10-Dec-2023",
                "successPercentage": "71%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "10-Dec-2023",
                "endDate": "13-Dec-2025",
                "successPercentage": "78%",
                "predictedDateL50": "28-Jun-2023",
                "predictedDateU50": "29-Apr-2024",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "13-Dec-2025",
                "endDate": "29-Apr-2028",
                "successPercentage": "66%",
                "predictedDateL50": "06-Dec-2024",
                "predictedDateU50": "19-May-2026",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Apr-2028",
                "endDate": "18-Jan-2029",
                "successPercentage": "95%",
                "predictedDateL50": "20-Apr-2027",
                "predictedDateU50": "17-Sep-2028",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "18-Jan-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "21-Oct-2028",
                "predictedDateU50": "22-Feb-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "21-Feb-2021",
                "milestoneExtendedDate": "",
                "notes": "In February 2021, positive data from phase Ib trial (NCT09610530) inpatients (n = 18) with solid tumor were reported.DLTs were not reported. The treatment emergent adverse events (TEAEs) reported in 17 patients. In arms A and C, the most common TEAE was rash (n = 3 each). In arm A, grade &gt;/= 3 TEAEs were observed in two patients; serious TEAEs were observed in 33.3% each, in arms A nad B, respectively [ <ulink linkID=\"2516001\" linkType=\"Reference\">  2516001 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "21-Feb-2021",
                "milestoneExtendedDate": "",
                "notes": "In February 2021, positive topline data from phase Ib trial (NCT09610530) in patients (n = 18) with solid tumor were reported. DLTs were not reported. The treatment emergent adverse events (TEAEs) reported in 17 patients. In arms A and C, the most common TEAE was rash (n = 3 each). In arm A, grade &gt;/= 3 TEAEs were observed in two patients; serious TEAEs were observed in 33.3% each, in arms A nad B, respectively.[ <ulink linkID=\"2516001\" linkType=\"Reference\">  2516001 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In April 2019, a phase Ib trial in patients with advanced solid tumor malignancies was expected to complete in December 2022 [ <ulink linkID=\"2140866\" linkType=\"Reference\">  2140866 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Feb-2015",
            "endDate": "17-Jan-2028",
            "statusDate": "28-Jul-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "55%",
            "timeToRegistration": "4.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Feb-2015",
                "endDate": "29-Sep-2024",
                "successPercentage": "88%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "9.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "29-Sep-2024",
                "endDate": "21-Mar-2027",
                "successPercentage": "66%",
                "predictedDateL50": "14-Feb-2024",
                "predictedDateU50": "13-Apr-2025",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Mar-2027",
                "endDate": "16-Dec-2027",
                "successPercentage": "95%",
                "predictedDateL50": "23-Feb-2026",
                "predictedDateU50": "07-Aug-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "16-Dec-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Sep-2027",
                "predictedDateU50": "17-Jan-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Nov-2017",
                "milestoneExtendedDate": "",
                "notes": "In November 2018, interim data were presented at the Annual Scientific Meeting of the Society for Immunotherapy of Cancer in Washington, DC. The half-life at INCMGA-00012 3 mg/kg q2w and 500 mg q4w was 17 and 14 days, respectively. AEs of special interests included colitis, infusion-related reaction, liver function abnormality, endocrine disorders, rash, diarrhea, hyperglycemia, myocarditis, nephritis and pain in extremity [ <ulink linkID=\"2093393\" linkType=\"Reference\">  2093393 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Feb-2015",
            "endDate": "29-Apr-2028",
            "statusDate": "30-Nov-2016",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "61%",
            "timeToRegistration": "4.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Feb-2015",
                "endDate": "29-Sep-2024",
                "successPercentage": "89%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "9.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "29-Sep-2024",
                "endDate": "17-Apr-2027",
                "successPercentage": "72%",
                "predictedDateL50": "14-Feb-2024",
                "predictedDateU50": "13-Apr-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-Apr-2027",
                "endDate": "21-Mar-2028",
                "successPercentage": "95%",
                "predictedDateL50": "13-Mar-2026",
                "predictedDateU50": "02-Sep-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-Mar-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Dec-2027",
                "predictedDateU50": "29-Apr-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Nov-2017",
                "milestoneExtendedDate": "",
                "notes": "In November 2018, interim data were presented at the Annual Scientific Meeting of the Society for Immunotherapy of Cancer in Washington, DC. The half-life at INCMGA-00012 3 mg/kg q2w and 500 mg q4w was 17 and 14 days, respectively. AEs of special interests included colitis, infusion-related reaction, liver function abnormality, endocrine disorders, rash, diarrhea, hyperglycemia, myocarditis, nephritis and pain in extremity [ <ulink linkID=\"2093393\" linkType=\"Reference\">  2093393 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "4250",
              "name": "Metastatic renal cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Jan-2019",
            "endDate": "06-Jan-2027",
            "statusDate": "19-Dec-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "28%",
            "timeToRegistration": "3.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "09-Jan-2019",
                "endDate": "10-Dec-2023",
                "successPercentage": "88%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "07-Mar-2026",
                "successPercentage": "34%",
                "predictedDateL50": "14-May-2023",
                "predictedDateU50": "27-May-2024",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Mar-2026",
                "endDate": "03-Dec-2026",
                "successPercentage": "93%",
                "predictedDateL50": "14-Mar-2025",
                "predictedDateU50": "26-Jul-2026",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "03-Dec-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Sep-2026",
                "predictedDateU50": "06-Jan-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "07-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, positive data were presented from a phase II study (NCT03679767) in patients with NSCLC, urothelial cancer, metastatic melanoma and RCC [ <ulink linkID=\"2474950\" linkType=\"Reference\">  2474950 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "17216",
              "name": "Incyte Corp"
            },
            "indication": {
              "id": "4250",
              "name": "Metastatic renal cell carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "19-Dec-2018",
            "endDate": "03-Mar-2027",
            "statusDate": "19-Dec-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "29%",
            "timeToRegistration": "3.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "19-Dec-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "89%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "07-Mar-2026",
                "successPercentage": "35%",
                "predictedDateL50": "14-May-2023",
                "predictedDateU50": "27-May-2024",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Mar-2026",
                "endDate": "22-Jan-2027",
                "successPercentage": "92%",
                "predictedDateL50": "14-Mar-2025",
                "predictedDateU50": "26-Jul-2026",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Jan-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "12-Oct-2026",
                "predictedDateU50": "03-Mar-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "07-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, positive data were presented from a phase II study (NCT03679767) in patients with NSCLC, urothelial cancer, metastatic melanoma and RCC [ <ulink linkID=\"2474950\" linkType=\"Reference\">  2474950 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      }
    ]
  }